RESULT_COUNT: 352,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
CORT,CORT:US,BBG000BKJG33,"Innoviva Clears Key Benchmark, Hitting 80-Plus RS Rating",2017-10-20 16:07:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/feHZr-ih0Ts/innoviva-clears-key-benchmark-hitting-80-plus-rs-rating-cm862737,Innoviva INVA saw a welcome improvement to its Relative Strength RS Rating on Friday rising from 72 to 81 ibd display video id 2102289 width 50 float left autostart true IBD s proprietary rating tracks share price movement with a 1 worst to 99 best
CORT,CORT:US,BBG000BKJG33,Gilead Sciences Shows Rising Relative Price Performance; Still Shy Of Key Threshold,2017-10-20 16:05:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PaTnl58qEF0/gilead-sciences-shows-rising-relative-price-performance-still-shy-of-key-threshold-cm862718,The Relative Strength RS Rating for Gilead Sciences GILD entered a new percentile Friday as it got a lift from 68 to 73 ibd display video id 2360792 width 50 float left autostart true This unique rating identifies technical performance by showing how
CORT,CORT:US,BBG000BKJG33,"ETFs with exposure to Corcept Therapeutics, Inc. : October 20, 2017",2017-10-20 14:09:20 +0000,http://finance.yahoo.com/r/f60d59db-3805-3bc9-8bc7-047037802c79/etfs-with-exposure-to-corcept-therapeutics-inc-october-20-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Stocks Showing Market Leadership: PTC Therapeutics Earns 92 RS Rating,2017-10-17 14:54:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8GvxdIyFhQ4/stocks-showing-market-leadership-ptc-therapeutics-earns-92-rs-rating-cm860690,PTC Therapeutics PTCT saw a welcome improvement to its Relative Strength RS Rating on Tuesday with an increase from 81 to 92 ibd display video id 449419 width 50 float left autostart true This proprietary rating measures market leadership by showing how
CORT,CORT:US,BBG000BKJG33,Exelixis Earns Relative Strength Rating Upgrade,2017-10-17 14:53:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JE_WDkUmyVw/exelixis-earns-relative-strength-rating-upgrade-cm860672,Exelixis EXEL saw a positive improvement to its Relative Strength RS Rating on Tuesday rising from 89 to 95 ibd display video id 2102289 width 50 float left autostart true IBD s proprietary RS Rating identifies market leadership by showing how a stock s
CORT,CORT:US,BBG000BKJG33,Stocks Showing Improving Market Leadership: Five Prime Therapeutics Earns 83 RS Rating,2017-10-16 15:21:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HR9yLMIVH3Y/stocks-showing-improving-market-leadership-five-prime-therapeutics-earns-83-rs-rating-cm860172,Five Prime Therapeutics FPRX had its Relative Strength RS Rating upgraded from 80 to 83 Monday ibd display video id 2102289 width 50 float left autostart true This unique rating tracks market leadership by showing how a stock s price movement over the last
CORT,CORT:US,BBG000BKJG33,Today's Research Reports on Trending Tickers: Corcept Therapeutics and Orexigen Therapeutics,2017-10-16 12:20:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-122000289.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / October 16, 2017 / U.S. markets rose Friday to close the week in the green as investors appear to be expecting a strong earnings season. The Dow Jones Industrial Average gained ..."
CORT,CORT:US,BBG000BKJG33,Intra-Cellular Therapies Shows Rising Price Performance With Jump To 83 RS Rating,2017-10-12 15:17:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NwExEYVWiwg/intra-cellular-therapies-shows-rising-price-performance-with-jump-to-83-rs-rating-cm858868,On Thursday Intra Cellular Therapies ITCI reached an important technical milestone with its Relative Strength RS Rating jumping into the 80 plus percentile with an upgrade to 83 a rise from 80 the day before ibd display video id 449433 width 50 float
CORT,CORT:US,BBG000BKJG33,Stocks With Rising Relative Price Strength: Ionis Pharmaceuticals,2017-10-12 15:17:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HTGBb3nrq3c/stocks-with-rising-relative-price-strength-ionis-pharmaceuticals-cm858866,On Thursday Ionis Pharmaceuticals IONS hit an important performance benchmark with its Relative Strength RS Rating moving into the 90 plus percentile with an improvement to 91 an increase from 88 the day before ibd display video id 449419 width 50 float
CORT,CORT:US,BBG000BKJG33,Aerie Pharmaceuticals Scores Relative Strength Rating Upgrade,2017-10-12 15:16:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FC964KSpffo/aerie-pharmaceuticals-scores-relative-strength-rating-upgrade-cm858864,On Thursday Aerie Pharmaceuticals AERI hit an important technical milestone with its Relative Strength RS Rating jumping into the 90 plus percentile with an improvement to 93 a rise from 82 the day before ibd display video id 449423 width 50 float
CORT,CORT:US,BBG000BKJG33,Stocks Showing Rising Market Leadership: Aerie Pharmaceuticals Earns 82 RS Rating,2017-10-11 15:16:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/04zCniEIB4k/stocks-showing-rising-market-leadership-aerie-pharmaceuticals-earns-82-rs-rating-cm858237,When considering what names to put on your watch list focus on stocks with an 80 or higher RS Rating Aerie Pharmaceuticals AERI now meets that criteria with a jump from 74 to 82 Wednesday ibd display video id 2102289 width 50 float left autostart true IBD
CORT,CORT:US,BBG000BKJG33,Dow Returns to All-Time Highs,2017-10-11 14:13:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SdWrNWvoXoU/dow-returns-to-all-time-highs-cm857891,The October episode of the Zacks Ultimate Strategy Session is now available for viewing Tune in to this must see event when Sheraz Mian Eric Dutram Tracey Ryniec Neena Mishra CFA FRM and Kevin Cook discussed the investment landscape from most every angle Don t miss your chance to
CORT,CORT:US,BBG000BKJG33,"Weakness In Corcept Shares Is 'Overdone,' According To Analyst",2017-10-10 20:01:16 +0000,https://finance.yahoo.com/news/weakness-corcept-shares-overdone-according-200116977.html?.tsrc=rss,"Corcept Therapeurtics Incorporated (NASDAQ: CORT ) shares are down more than 7 percent Tuesday after the company seemingly reported a steep decline in Korlym prescriptions . However, the stock is bouncing ..."
CORT,CORT:US,BBG000BKJG33,Can Corcept Therapeutics Incorporatedâ€™s (CORT) ROE Continue To Surpass The Industry Average?,2017-10-10 17:39:15 +0000,https://finance.yahoo.com/news/corcept-therapeutics-incorporated-cort-roe-173915523.html?.tsrc=rss,"With an ROE of 52.76%, Corcept Therapeutics Incorporated (NASDAQ:CORT) outpaced its own industry which delivered a less exciting 18.27% over the past year. On the surface, this looks fantastic sinceRead More..."
CORT,CORT:US,BBG000BKJG33,Mid-Morning Market Update: Markets Open Higher; Wal-Mart Reports $20B Buyback Plan,2017-10-10 15:40:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FKKt-Ns0S0A/mid-morning-market-update-markets-open-higher-wal-mart-reports-20b-buyback-plan-cm857623,Following the market opening Tuesday the Dow traded up 0 23 percent to 22 813 71 while the NASDAQ climbed 0 11 percent to 6 586 90 The S amp P also rose gaining 0 19 percent to 2 549 49 Leading and Lagging Sectors Tuesday morning the non cyclical consumer goods amp
CORT,CORT:US,BBG000BKJG33,"ETFs with exposure to Corcept Therapeutics, Inc. : October 9, 2017",2017-10-09 15:24:50 +0000,http://finance.yahoo.com/r/e4a497bb-388f-30ce-a133-5c72f75e311c/etfs-with-exposure-to-corcept-therapeutics-inc-october-9-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,"Flexion Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating",2017-10-09 14:54:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JuT9Y_XEL74/flexion-therapeutics-clears-technical-benchmark-hitting-90-plus-rs-rating-cm857013,On Monday Flexion Therapeutics FLXN received an upgrade to its Relative Strength RS Rating from 85 to 92 ibd display video id 449419 width 50 float left autostart true This proprietary rating measures technical performance by using a 1 worst to 99
CORT,CORT:US,BBG000BKJG33,Flexion Therapeutics Hits 80-Plus Relative Strength Rating Benchmark,2017-10-06 15:48:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2Ny2LFc5T3k/flexion-therapeutics-hits-80-plus-relative-strength-rating-benchmark-cm856356,When considering what names to put on your watch list look for stocks with an 80 or higher RS Rating Flexion Therapeutics FLXN now meets that criteria with an increase from 80 to 85 Friday ibd display video id 2102289 width 50 float left autostart true IBD
CORT,CORT:US,BBG000BKJG33,Stocks Showing Improving Market Leadership: Intra-Cellular Therapies Earns 83 RS Rating,2017-10-06 15:48:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mdIP0PdveBU/stocks-showing-improving-market-leadership-intra-cellular-therapies-earns-83-rs-rating-cm856355,When building your watch list look for stocks with an 80 or higher RS Rating Intra Cellular Therapies ITCI just cleared that benchmark with an upgrade from 78 to 83 ibd display video id 449433 width 50 float left autostart true This exclusive rating from Investor
CORT,CORT:US,BBG000BKJG33,Stocks With Rising Relative Price Strength: Innoviva,2017-10-06 15:47:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H8WvCVQQrrM/stocks-with-rising-relative-price-strength-innoviva-cm856348,Innoviva INVA saw a positive improvement to its Relative Strength RS Rating on Friday rising from 78 to 82 ibd display video id 449423 width 50 float left autostart true This exclusive rating from Investor s Business Daily identifies market leadership with a
CORT,CORT:US,BBG000BKJG33,Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 92,2017-10-06 15:47:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/guIrSNRJUhs/stocks-to-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-to-92-cm856341,Adamas Pharmaceuticals ADMS saw a positive improvement to its Relative Strength RS Rating on Friday with an upgrade from 87 to 92 ibd display video id 449419 width 50 float left autostart true IBD s unique rating identifies market leadership with a 1 worst
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017",2017-10-06 13:03:28 +0000,http://finance.yahoo.com/r/c72cc3f9-417d-3afa-8d02-bc85f4d29068/corcept-therapeutics-inc-cort-us-earnings-analysis-q2-2017-by-the-numbers-october-6-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Corcept Therapeutics, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 35.56 million, Net Earnings of USD 12.65 million. Gross margins narrowed from 97.84% to 97.82% compared to the same period last year, operating (EBITDA) margins now 36.01% from 7.77%. Change in operating ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Stocks With Rising Relative Strength: Amgen,2017-10-05 14:53:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JGTD2v0qZew/stocks-with-rising-relative-strength-amgen-cm855785,In a welcome move Amgen AMGN saw its Relative Strength Rating improve from 70 to 73 on Thursday ibd display video id 449433 width 50 float left autostart true This proprietary rating identifies market leadership by using a 1 worst to 99 best score that
CORT,CORT:US,BBG000BKJG33,Global Blood Therapeutic Earns Relative Strength Rating Upgrade,2017-10-05 14:53:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dC2Ibj7Y5CY/global-blood-therapeutic-earns-relative-strength-rating-upgrade-cm855784,Global Blood Therapeutic GBT saw a positive improvement to its Relative Strength RS Rating on Thursday rising from 87 to 92 ibd display video id 2102289 width 50 float left autostart true This unique rating tracks technical performance by using a 1 worst to
CORT,CORT:US,BBG000BKJG33,Aerie Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold,2017-10-05 14:52:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kc8537qcLgg/aerie-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold-cm855781,On Thursday Aerie Pharmaceuticals AERI cleared a key technical benchmark with its Relative Strength RS Rating jumping into the 80 plus percentile with an improvement to 81 a rise from 74 the day before ibd display video id 2102289 width 50 float
CORT,CORT:US,BBG000BKJG33,Stocks With Rising Relative Strength: Intra-Cellular Therapies,2017-10-05 14:50:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GhiDt7LxnUU/stocks-with-rising-relative-strength-intra-cellular-therapies-cm855750,Intra Cellular Therapies ITCI saw a welcome improvement to its Relative Strength RS Rating on Thursday rising from 70 to 78 ibd display video id 449433 width 50 float left autostart true IBD s unique rating tracks share price performance with a 1 worst to
CORT,CORT:US,BBG000BKJG33,Aerie Pharmaceuticals Sees IBD RS Rating Climb To 73,2017-10-03 15:02:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rRZKsx0GOPc/aerie-pharmaceuticals-sees-ibd-rs-rating-climb-to-73-cm854621,The Relative Strength RS Rating for Aerie Pharmaceuticals AERI moved into a new percentile Tuesday as it got a lift from 65 to 73 ibd display video id 449433 width 50 float left autostart true IBD s unique RS Rating identifies market leadership by
CORT,CORT:US,BBG000BKJG33,Stocks Showing Rising Market Leadership: Flexion Therapeutics Earns 85 RS Rating,2017-10-03 15:01:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zIwj4I-3Cmk/stocks-showing-rising-market-leadership-flexion-therapeutics-earns-85-rs-rating-cm854615,Flexion Therapeutics FLXN saw a positive improvement to its Relative Strength RS Rating on Tuesday rising from 78 to 85 ibd display video id 449419 width 50 float left autostart true This exclusive rating from Investor s Business Daily measures share
CORT,CORT:US,BBG000BKJG33,Acorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating,2017-10-03 15:01:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6volWQtxWYY/acorda-therapeutics-shows-market-leadership-with-jump-to-91-rs-rating-cm854609,Acorda Therapeutics ACOR saw a welcome improvement to its Relative Strength RS Rating on Tuesday rising from 80 to 91 ibd display video id 449433 width 50 float left autostart true This exclusive rating from Investor s Business Daily tracks share price
CORT,CORT:US,BBG000BKJG33,Stocks With Rising Relative Price Strength: Innoviva,2017-10-03 15:01:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zi_sYHT9lXU/stocks-with-rising-relative-price-strength-innoviva-cm854608,The Relative Strength RS Rating for Innoviva INVA jumped into a new percentile Tuesday with an increase from 79 to 82 ibd display video id 449423 width 50 float left autostart true This exclusive rating from Investor s Business Daily tracks market
CORT,CORT:US,BBG000BKJG33,"Ionis Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating",2017-10-03 15:00:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lV3llHuggT0/ionis-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-cm854602,One important metric to look for in a stock is an 80 or higher Relative Strength Rating Ionis Pharmaceuticals IONS cleared that benchmark Tuesday with a jump from 74 to 82 Tuesday ibd display video id 449419 width 50 float left autostart true IBD s unique RS
CORT,CORT:US,BBG000BKJG33,Flexion Therapeutics Sees Relative Strength Rating Improve To 75,2017-09-29 14:38:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KrGJhZAgoEQ/flexion-therapeutics-sees-relative-strength-rating-improve-to-75-cm853122,The Relative Strength RS Rating for Flexion Therapeutics FLXN entered a higher percentile Friday as it got a lift from 69 to 75 ibd display video id 2102289 width 50 float left autostart true This proprietary rating tracks technical performance by using a
CORT,CORT:US,BBG000BKJG33,Ionis Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark,2017-09-29 14:38:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HnMtzplTfU0/ionis-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-cm853118,When building your watch list focus on stocks with an 80 or higher RS Rating Ionis Pharmaceuticals IONS now meets that criteria with an increase from 75 to 81 Friday ibd display video id 2102289 width 50 float left autostart true This proprietary rating
CORT,CORT:US,BBG000BKJG33,Adamas Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark,2017-09-29 14:36:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DLRGQQPPx1A/adamas-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-cm853090,One important metric to look for in a stock is an 80 or higher Relative Strength Rating Adamas Pharmaceuticals ADMS just hit that mark with a jump from 79 to 84 Friday ibd display video id 449433 width 50 float left autostart true IBD s proprietary RS Rating
CORT,CORT:US,BBG000BKJG33,Stocks Flashing Renewed Technical Strength: Acceleron Pharma,2017-09-29 14:35:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W8XKA7lNm1E/stocks-flashing-renewed-technical-strength-acceleron-pharma-cm853086,The Relative Strength RS Rating for Acceleron Pharma XLRN climbed into a new percentile Friday with an increase from 79 to 84 ibd display video id 449423 width 50 float left autostart true This exclusive rating from Investor s Business Daily identifies
CORT,CORT:US,BBG000BKJG33,Clovis Oncology Scores Relative Strength Rating Upgrade,2017-09-28 14:44:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ExXVg4f2oQA/clovis-oncology-scores-relative-strength-rating-upgrade-cm852533,Clovis Oncology CLVS saw a positive improvement to its Relative Strength RS Rating on Thursday with an upgrade from 88 to 92 ibd display video id 449419 width 50 float left autostart true IBD s unique RS Rating identifies market leadership by showing how
CORT,CORT:US,BBG000BKJG33,Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark,2017-09-27 14:57:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xj7b6r-WRPM/acceleron-pharma-reaches-80-plus-relative-strength-rating-benchmark-cm851895,Acceleron Pharma XLRN saw a positive improvement to its Relative Strength RS Rating on Wednesday rising from 77 to 81 ibd display video id 449419 width 50 float left autostart true IBD s proprietary rating tracks market leadership with a 1 worst to 99
CORT,CORT:US,BBG000BKJG33,Stocks Flashing Renewed Technical Strength: Innoviva,2017-09-27 14:57:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xmHlGvhHS0Q/stocks-flashing-renewed-technical-strength-innoviva-cm851883,When considering what names to put on your watch list look for stocks with an 80 or higher RS Rating Innoviva INVA just cleared that benchmark with an upgrade from 77 to 81 ibd display video id 449423 width 50 float left autostart true IBD s proprietary RS
CORT,CORT:US,BBG000BKJG33,Stocks To Watch: Prothena Sees Relative Strength Rating Jump To 81,2017-09-27 14:56:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ucZemWcA9k4/stocks-to-watch-prothena-sees-relative-strength-rating-jump-to-81-cm851877,One important metric to look for in a stock is an 80 or higher Relative Strength Rating Prothena PRTA now clears that threshold with a jump from 78 to 81 Wednesday ibd display video id 449419 width 50 float left autostart true IBD s proprietary RS Rating
CORT,CORT:US,BBG000BKJG33,Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating,2017-09-27 14:56:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o6gKLKDVRVA/stocks-showing-market-leadership-sarepta-therapeutics-earns-91-rs-rating-cm851869,Sarepta Therapeutics SRPT had its Relative Strength RS Rating upgraded from 87 to 91 Wednesday ibd display video id 449433 width 50 float left autostart true IBD s unique RS Rating measures technical performance by showing how a stock s price action over the
CORT,CORT:US,BBG000BKJG33,Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating,2017-09-27 07:00:00 +0000,http://finance.yahoo.com/r/f208b781-1549-3880-ab1c-6238b7e693cf/stocks-showing-market-leadership-sarepta-therapeutics-earns-91-rs-rating?src=A00220&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating."
CORT,CORT:US,BBG000BKJG33,Stocks Flashing Renewed Technical Strength: Innoviva,2017-09-27 07:00:00 +0000,http://finance.yahoo.com/r/4fded98e-5403-3b86-8586-cb5d810a390b/stocks-flashing-renewed-technical-strength-innoviva?src=A00220&yptr=yahoo&.tsrc=rss,"Innoviva shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81."
CORT,CORT:US,BBG000BKJG33,Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark,2017-09-27 07:00:00 +0000,http://finance.yahoo.com/r/3fb34c9f-68cf-3bb4-ab3f-d69df8e9cc87/acceleron-pharma-reaches-80-plus-relative-strength-rating-benchmark?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Acceleron Pharma shows improving technical performance.
CORT,CORT:US,BBG000BKJG33,Acceleron Pharma Trying To Close In On Key Technical Measure,2017-09-26 14:58:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fQCHZu6bTPo/acceleron-pharma-trying-to-close-in-on-key-technical-measure-cm851113,Acceleron Pharma XLRN had its Relative Strength RS Rating upgraded from 67 to 77 Tuesday a welcome improvement but still below the 80 or higher score you prefer to see ibd display video id 449419 width 50 float left autostart true IBD s unique RS
CORT,CORT:US,BBG000BKJG33,Acorda Therapeutics Getting Closer To Key Technical Measure,2017-09-26 14:57:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5V-QSgc-zpU/acorda-therapeutics-getting-closer-to-key-technical-measure-cm851105,Acorda Therapeutics ACOR saw a welcome improvement to its Relative Strength RS Rating on Tuesday rising from 67 to 78 ibd display video id 449433 width 50 float left autostart true IBD s unique rating measures market leadership with a 1 worst to 99
CORT,CORT:US,BBG000BKJG33,"Global Blood Therapeutic Clears Technical Benchmark, Hitting 80-Plus RS Rating",2017-09-26 14:55:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-b79O5RoKjM/global-blood-therapeutic-clears-technical-benchmark-hitting-80-plus-rs-rating-cm851071,The Relative Strength RS Rating for Global Blood Therapeutic GBT climbed into a new percentile Tuesday with an increase from 78 to 82 ibd display video id 449433 width 50 float left autostart true IBD s unique rating tracks market leadership with a 1
CORT,CORT:US,BBG000BKJG33,3 Bargain Biotech Stocks You Can Buy Today,2017-09-26 12:52:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rBf9Fang0KY/3-bargain-biotech-stocks-you-can-buy-today-cm850823,You might have heard that the stock market is overpriced after years of solid gains And it is That doesn t mean every stock is overpriced though Actually several biotech stocks look attractively valued right now Here s why AbbVie NYSE ABBV Celgene NASDAQ
CORT,CORT:US,BBG000BKJG33,Is It Too Late To Buy Corcept Therapeutics Incorporated (CORT)?,2017-09-26 11:38:12 +0000,https://finance.yahoo.com/news/too-buy-corcept-therapeutics-incorporated-113812874.html?.tsrc=rss,"Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM in the over the last fewRead More..."
CORT,CORT:US,BBG000BKJG33,3 Bargain Biotech Stocks You Can Buy Today,2017-09-26 11:17:00 +0000,http://finance.yahoo.com/r/6e0a8259-1098-31d5-9281-b594c45df4bd/3-bargain-biotech-stocks-you-can-buy-today.aspx?yptr=yahoo&.tsrc=rss,Spectacular growth prospects make these three biotech stocks look like steals right now.
CORT,CORT:US,BBG000BKJG33,Acorda Therapeutics Getting Closer To Key Technical Measure,2017-09-26 07:00:00 +0000,http://finance.yahoo.com/r/1a84de45-b9ae-39ea-8707-4a3f7d8596e1/acorda-therapeutics-getting-closer-to-key-technical-measure?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Acorda Therapeutics shows improving technical performance. Will it continue?
CORT,CORT:US,BBG000BKJG33,CORT Crosses Above Average Analyst Target,2017-09-25 13:47:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-GcxON8Sscc/cort-crosses-above-average-analyst-target-cm850254,In recent trading shares of Corcept Therapeutics Inc Symbol CORT have crossed above the average analyst 12 month target price of 17 75 changing hands for 18 20 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
CORT,CORT:US,BBG000BKJG33,3 Highest-Growth Stocks in the Market Today,2017-09-25 12:50:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mOnpl33F34E/3-highest-growth-stocks-in-the-market-today-cm850240,Which stocks claim the highest growth rates in the entire market The answer depends on how you define growth There are several kinds of growth sales earnings stock price cash flow and more Growth also requires a definition of time frame The highest growth stocks over the
CORT,CORT:US,BBG000BKJG33,3 Highest-Growth Stocks in the Market Today,2017-09-25 11:04:00 +0000,http://finance.yahoo.com/r/ea9f6fe8-39c2-3580-b3f2-71d0e7929f28/3-highest-growth-stocks-in-the-market-today-2.aspx?yptr=yahoo&.tsrc=rss,One of them you can watch -- literally.
CORT,CORT:US,BBG000BKJG33,Interesting CORT Put And Call Options For May 2018,2017-09-20 17:39:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pNfe93CLVbM/interesting-cort-put-and-call-options-for-may-2018-cm848537,Investors in Corcept Therapeutics Inc Symbol CORT saw new options become available this week for the May 2018 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 240 days until expiration the newly available
CORT,CORT:US,BBG000BKJG33,4 Biotech Stocks That Show Promise on Sustainable Growth,2017-09-14 21:39:09 +0000,https://finance.yahoo.com/news/4-biotech-stocks-show-promise-213909579.html?.tsrc=rss,"Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products."
CORT,CORT:US,BBG000BKJG33,3 Stocks That Have Doubled This Year,2017-09-14 16:39:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HuiWAyU5l1M/3-stocks-that-have-doubled-this-year-cm845763,All investors are happy to see even a modest raise in their stock holdings On the back of this long bull market we re currently riding there are a number of companies that have enjoyed quite a big jump In fact my research indicates that around 320 stocks have gone up at least 100
CORT,CORT:US,BBG000BKJG33,3 Stocks That Have Doubled This Year,2017-09-14 15:11:00 +0000,http://finance.yahoo.com/r/dfbeb76d-83ae-3bbf-ba3d-f0d582946176/3-stocks-that-have-doubled-this-year.aspx?yptr=yahoo&.tsrc=rss,Here&apos;s a trio of companies that have risen by 100% or more so far in 2017.
CORT,CORT:US,BBG000BKJG33,7 Buy-Ranked Stocks That Just Touched New All-Time Highs,2017-08-30 19:49:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-AcqwuLvcus/7-buy-ranked-stocks-that-just-touched-new-all-time-highs-cm839346,After a sluggish start to the trading week stocks turned a corner on Tuesday afternoon and started to surge higher That momentum continued on Wednesday and the major indices were all in the green by the end of morning trading hours August has proven to be one of the few challenging months
CORT,CORT:US,BBG000BKJG33,Harry Boxerâ€™s four biotech stocks to watch,2017-08-30 16:00:49 +0000,http://finance.yahoo.com/r/88d9678e-659d-3d9d-adf5-1057537a98cf/Story.aspx?guid=F333AF90-8D9A-11E7-870C-6A0275252EA1&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"In focus: Abeona Therapeutics, Corcept Therapeutics, ImmunoGen and Sangamo Therapeutics."
CORT,CORT:US,BBG000BKJG33,Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe,2017-08-30 15:54:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uq0Y531Kt1M/pfizers-snda-for-bosulif-accepted-in-the-us-and-europe-cm839183,Pfizer Inc PFE and partner Avillion announced that a supplemental New Drug Application sNDA for Bosulif has been accepted and granted priority review by the FDA We remind investors that Bosulif is currently approved for the treatment of chronic accelerated or blast phase
CORT,CORT:US,BBG000BKJG33,Pfizer&apos;s sNDA for Bosulif Accepted in the U.S. and Europe,2017-08-30 13:17:01 +0000,https://finance.yahoo.com/news/pfizer-apos-snda-bosulif-accepted-131701111.html?.tsrc=rss,Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.
CORT,CORT:US,BBG000BKJG33,Top Ranked Momentum Stocks to Buy for August 29th,2017-08-29 17:52:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tZqrvR4v1pY/top-ranked-momentum-stocks-to-buy-for-august-29th-cm838773,Here are four stocks with buy rank and strong momentum characteristics for investors to consider today August 29th Home Depot Inc HD This home improvement retailer has a Zacks Rank 2 Buy and witnessed the Zacks Consensus Estimate for its current year earnings rising 1 1 over the
CORT,CORT:US,BBG000BKJG33,Top Ranked Momentum Stocks to Buy for August 29th,2017-08-29 14:36:02 +0000,https://finance.yahoo.com/news/top-ranked-momentum-stocks-buy-143602445.html?.tsrc=rss,Top Ranked Momentum Stocks to Buy for August 29th
CORT,CORT:US,BBG000BKJG33,"Cramer's lightning round: I know I'm alone here, but I st...",2017-08-28 23:04:00 +0000,https://finance.yahoo.com/video/cramers-lightning-round-know-im-230400566.html?.tsrc=rss,"Jim Cramer flies through his take on callers' favorite stocks, including one airline play."
CORT,CORT:US,BBG000BKJG33,"Cramer&apos;s lightning round: I know I&apos;m alone here, but I still like the airlines",2017-08-28 22:48:30 +0000,https://finance.yahoo.com/news/cramer-apos-lightning-round-know-224830984.html?.tsrc=rss,"Jim Cramer flies through his take on callers&apos; favorite stocks, including one airline play."
CORT,CORT:US,BBG000BKJG33,"Cramer's lightning round: I know I'm alone here, but I still like the airlines",2017-08-28 22:48:30 +0000,http://finance.yahoo.com/r/a7e17299-4142-3317-9c88-85f5820b75f6/104676764?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104676764&yptr=yahoo&.tsrc=rss,"Jim Cramer flies through his take on callers' favorite stocks, including one airline play."
CORT,CORT:US,BBG000BKJG33,Mylan and Otsuka Ink Agreement to Commercialize Deltyba,2017-08-25 17:40:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DsK3Ay1t5rc/mylan-and-otsuka-ink-agreement-to-commercialize-deltyba-cm837283,Mylan N V MYL and Japan based Otsuka Pharmaceutical signed a license agreementto commercialize Deltyba delamanid in low and middle income countries including South Africa and India The drug is approved for treatment of pulmonary multidrug resistant tuberculosis MDR TB in adults
CORT,CORT:US,BBG000BKJG33,"Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars",2017-08-25 16:41:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VuuCbJmZCm4/adamas-adms-dyskinesia-drug-gets-fda-approval-stock-soars-cm837203,Adamas Pharmaceuticals Inc ADMS announced FDA approval of its Gocovri for treating dyskinesia in patients with Parkinson s disease who are on levodopa based therapy This the first drug to receive approval for this indication in the U S The approved dosage for Gocovri extended release
CORT,CORT:US,BBG000BKJG33,Mylan and Otsuka Ink Agreement to Commercialize Deltyba,2017-08-25 15:09:03 +0000,https://finance.yahoo.com/news/mylan-otsuka-ink-agreement-commercialize-150903099.html?.tsrc=rss,Mylan (MYL) and Otsuka Pharmaceutical have entered into a license agreement to commercialize Deltyba in developing countries.
CORT,CORT:US,BBG000BKJG33,"Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars",2017-08-25 14:45:02 +0000,https://finance.yahoo.com/news/adamas-adms-dyskinesia-drug-gets-144502091.html?.tsrc=rss,Adamas Pharmaceuticals&apos; (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson&apos;s disease. This led to an upside in shares.
CORT,CORT:US,BBG000BKJG33,"Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View",2017-08-24 17:39:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_i49UMeyNcI/lannett-lci-q4-earnings-in-line-stock-up-on-solid-view-cm836702,Lannett Company Inc LCI reported earnings of 40 cents per share in fiscal fourth quarter of 2017 which were in line with the Zacks Consensus Estimate The company had reported earnings of 73 cents per share in the year ago quarter Lannett s shares rose 1 8 in after hours trading on
CORT,CORT:US,BBG000BKJG33,BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End,2017-08-24 17:37:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jMoQ6Ip5MnA/biodelivery-bdsi-ceo-mark-sirgo-to-retire-by-2017-end-cm836666,BioDelivery Sciences International Inc BDSI announced the retirement of its chief executive officer CEO for the last 12 years Dr Mark A Sirgo by the end of 2017 Sirgo also held the position of president of BioDelivery Sciences However he will continue to serve as vice chairman of
CORT,CORT:US,BBG000BKJG33,BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End,2017-08-24 15:55:03 +0000,https://finance.yahoo.com/news/biodelivery-bdsi-ceo-mark-sirgo-155503115.html?.tsrc=rss,"BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year."
CORT,CORT:US,BBG000BKJG33,"Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View",2017-08-24 14:57:02 +0000,https://finance.yahoo.com/news/lannett-lci-q4-earnings-line-145702803.html?.tsrc=rss,"Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018."
CORT,CORT:US,BBG000BKJG33,4 of the Highest-Growth Stocks in Biotech Today,2017-08-24 14:35:00 +0000,http://finance.yahoo.com/r/2c003ae5-c604-3e98-b01c-63fda8d763e8/4-of-the-highest-growth-stocks-in-biotech-today.aspx?yptr=yahoo&.tsrc=rss,"How does a compound annual growth rate of 50%, 60%, or 70% sound?"
CORT,CORT:US,BBG000BKJG33,Today's Research Reports on Trending Tickers: Corcept Therapeutics Inc. and Opko Health Inc.,2017-08-18 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000718.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 18, 2017 / U.S. markets tumbled Thursday on news of a terrorist attack in London and growing concerns that the recent controversies surrounding President Trump would ..."
CORT,CORT:US,BBG000BKJG33,Three Stocks Breaking Out,2017-08-16 18:21:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S79PCQ2nNS4/three-stocks-breaking-out-cm832934,"By Harry Boxer,  TheTechTrader.com       Three stocks breaking out of consolidation patterns lead our charts to watch today, while one trending lower is highlighted as a potential short.  Corcept Therapeutics Incorporated ( CORT ) climbed 87 cents, or 6.2%, to close at $14.87 on 1.6 million shares traded Tuesday."
CORT,CORT:US,BBG000BKJG33,"Three Breakouts, And One Possible Breakdown In Cummins",2017-08-16 17:43:00 +0000,http://finance.yahoo.com/r/1063195d-e38f-3f63-a8c9-7c78addde0cf/three-breakouts-and-one-possible-breakdown-in-cummins?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Three stocks breaking out of consolidation patterns lead our charts to watch today, while one trending lower is highlighted as a potential short."
CORT,CORT:US,BBG000BKJG33,Three Stocks Breaking Out,2017-08-16 16:58:35 +0000,https://finance.yahoo.com/news/three-stocks-breaking-165835138.html?.tsrc=rss,"Three stocks breaking out of consolidation patterns lead our charts to watch today, while one trending lower is highlighted as a potential short. Corcept Therapeutics Incorporated (NASDAQ; CORT) climbed ..."
CORT,CORT:US,BBG000BKJG33,"Signet Jewelers could fall further, and 3 more stocks to watch",2017-08-16 15:40:11 +0000,http://finance.yahoo.com/r/b8549322-c0dc-32b2-886d-597717b901cb/Story.aspx?guid=8538211E-8297-11E7-B760-5B960B8E2619&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Harry Boxer lists four stocks
CORT,CORT:US,BBG000BKJG33,What's a Retailer To Do?,2017-08-16 13:35:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-kaiweU-u5Q/whats-a-retailer-to-do-cm832542,The retailers did their best to keep yesterday s strong rally going but it wasn t enough Retail sales in July were better than expected and Home Depot reported a solid quarter Nevertheless consumer related stocks were among the biggest losers today including a surprising dip of more than 2
CORT,CORT:US,BBG000BKJG33,Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge,2017-08-14 14:41:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y-DdMNLI3hI/why-corcept-therapeutics-cort-could-be-positioned-for-a-surge-cm831615,Corcept Therapeutics Incorporated CORT is a pharmaceutical company that could be an interesting play for investors That is because not only does the stock have decent short term momentum but it is seeing solid activity on the earnings estimate revision front as well These positive
CORT,CORT:US,BBG000BKJG33,Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge,2017-08-14 12:33:12 +0000,https://finance.yahoo.com/news/why-corcept-therapeutics-cort-could-123312568.html?.tsrc=rss,"Corcept Therapeutics (CORT) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors."
CORT,CORT:US,BBG000BKJG33,Edited Transcript of CORT earnings conference call or presentation 1-Aug-17 9:00pm GMT,2017-08-12 23:50:46 +0000,https://finance.yahoo.com/news/edited-transcript-cort-earnings-conference-125828437.html?.tsrc=rss,Q2 2017 Corcept Therapeutics Inc Earnings Call
CORT,CORT:US,BBG000BKJG33,Can The Uptrend Continue for Corcept Therapeutics (CORT)?,2017-08-09 12:36:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8vhzhSOvsT8/can-the-uptrend-continue-for-corcept-therapeutics-cort-cm829217,Investors certainly have to be happy with Corcept Therapeutics Incorporated CORT and its short term performance After all the stock has jumped by 25 5 in the past 4 weeks and it is also above its 20 Day Simple Moving Average as well This is certainly a good trend but investors are
CORT,CORT:US,BBG000BKJG33,Can The Uptrend Continue for Corcept Therapeutics (CORT)?,2017-08-09 10:05:10 +0000,https://finance.yahoo.com/news/uptrend-continue-corcept-therapeutics-cort-100510164.html?.tsrc=rss,Investors certainly have to be happy with Corcept Therapeutics Incorporated (CORT) and its short term performance
CORT,CORT:US,BBG000BKJG33,Top Ranked Momentum Stocks to Buy for August 7th,2017-08-07 15:43:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W2mlzK6T_Gs/top-ranked-momentum-stocks-to-buy-for-august-7th-cm828193,Here are four stocks with buy rank and strong momentum characteristics for investors to consider today August 7th Corcept Therapeutics Incorporated CORT This pharmaceutical company has a Zacks Rank 2 Buy and witnessed the Zacks Consensus Estimate for its current year earnings
CORT,CORT:US,BBG000BKJG33,Top Ranked Momentum Stocks to Buy for August 7th,2017-08-07 13:15:01 +0000,https://finance.yahoo.com/news/top-ranked-momentum-stocks-buy-131501146.html?.tsrc=rss,Top Ranked Momentum Stocks to Buy for August 7th
CORT,CORT:US,BBG000BKJG33,These two biotech stocks are breaking out,2017-08-03 17:27:28 +0000,http://finance.yahoo.com/r/49f08f05-b744-340a-876d-c34d2ac42f7b/Story.aspx?guid=527D8610-786F-11E7-AA20-463FA534051F&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Trader Harry Boxer reports on Corcept Therapeutics and Dynavax Technologies.
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session,2017-08-03 13:03:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpn3SWrn1PA/corcept-cort-looks-good-stock-moves-up-88-in-session-cm826307,Corcept Therapeutics Incorporated CORT was a big mover last session as its shares rose over 8 on the day The move came after the company delivered robust second quarter 2017 results This breaks the recent trend of the company as the stock is now trading above the volatile price range
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session,2017-08-03 12:15:12 +0000,https://finance.yahoo.com/news/corcept-cort-looks-good-stock-121512819.html?.tsrc=rss,"Corcept Therapeutics Incorporated (CORT) moved big last session, as its shares rose over 8% on the day."
CORT,CORT:US,BBG000BKJG33,Why Corcept Therapeutics Incorporated Stock Surged Higher Today,2017-08-02 23:55:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uOTIW0TNt5s/why-corcept-therapeutics-incorporated-stock-surged-higher-today-cm826141,What happened Shares of the rare disease specialist Corcept Therapeutics Incorporated NASDAQ CORT rose by 8 78 on heavy volume today due to a stronger than expected second quarter earnings report Specifically the drugmaker easily beat consensus for both revenue and earnings
CORT,CORT:US,BBG000BKJG33,Why Corcept Therapeutics Incorporated Stock Surged Higher Today,2017-08-02 22:21:00 +0000,http://finance.yahoo.com/r/32a319f4-ec96-32e7-8ee8-3eed60096b65/why-corcept-therapeutics-inc-stock-surged-higher-t.aspx?yptr=yahoo&.tsrc=rss,"Corcept&apos;s drug for Cushingâ€™s syndrome, Korlym, is exceeding expectations."
CORT,CORT:US,BBG000BKJG33,How These 2 Biotechs Defied The Downtrend To Hit Fresh Highs,2017-08-02 20:21:07 +0000,http://finance.yahoo.com/r/db040190-9559-3152-9ffe-f86787133ada/how-these-2-biotechs-defied-the-downtrend-to-hit-fresh-highs?src=A00220&yptr=yahoo&.tsrc=rss,Spark and Corcept defied a downtrend in the biotech sector Wednesday and instead rocketed to fresh highs on strong second-quarter reports.
CORT,CORT:US,BBG000BKJG33,"Health Care Sector Update for 08/02/2017: CORT,ONCE,COTV",2017-08-02 18:56:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1OiwyOxkxZY/health-care-sector-update-for-08022017-cortoncecotv-cm825997,Top Health Care StocksTop Health Care Stocks JNJ 0 47 JNJ 0 47 PFE 0 12 PFE 0 12 ABT 0 07 ABT 0 07 MRK 0 84 MRK 0 84 AMGN 0 12 AMGN 0 12 Health care stocks were trimming some of their losses this afternoon with the NYSE Health Care Index sliding to a 0 2 decline while shares
CORT,CORT:US,BBG000BKJG33,"Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised",2017-08-02 17:00:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Li-Pjlf1kMM/corcept-cort-q2-earnings-beat-estimates-guidance-raised-cm825879,Corcept Therapeutics Incorporated s CORT adjusted second quarter 2017 earnings including stock based compensation expense of 10 cents per share surpassed the Zacks Consensus Estimate of 8 cents 160 The reported figure also topped the year ago adjusted earnings of 1 cent Revenues
CORT,CORT:US,BBG000BKJG33,"Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised",2017-08-02 14:24:02 +0000,https://finance.yahoo.com/news/corcept-cort-q2-earnings-beat-142402572.html?.tsrc=rss,Corcept Therapeutics Incorporated&apos;s (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.
CORT,CORT:US,BBG000BKJG33,Corcept beats 2Q profit forecasts,2017-08-02 03:14:50 +0000,https://finance.yahoo.com/news/corcept-beats-2q-profit-forecasts-221424648.html?.tsrc=rss,"On a per-share basis, the Menlo Park, California-based company said it had profit of 10 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ..."
CORT,CORT:US,BBG000BKJG33,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount",2017-08-02 02:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NKjz_8xnheE/fda-nod-for-agios-idhifa-bmy-expands-opdivo-use-ocul-reduces-headcount-20170802-00079,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount"
CORT,CORT:US,BBG000BKJG33,"ETFs with exposure to Corcept Therapeutics, Inc. : August 1, 2017",2017-08-01 20:27:11 +0000,http://finance.yahoo.com/r/058b8981-7732-3861-b190-8b20eedeff60/etfs-with-exposure-to-corcept-therapeutics-inc-august-1-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update",2017-08-01 20:05:00 +0000,https://finance.yahoo.com/news/corcept-therapeutics-announces-second-quarter-200500293.html?.tsrc=rss,"Revenue of $35.6 million in second quarter 2017, an increase of 80 percent from second quarter 2016 2017 revenue guidance increased by $20 million, to $145-155 million GAAP net income of $0.10 per share, ..."
CORT,CORT:US,BBG000BKJG33,CORT Crosses Above Average Analyst Target,2017-08-01 13:54:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wPZUfkIhvzc/cort-crosses-above-average-analyst-target-cm824743,In recent trading shares of Corcept Therapeutics Inc Symbol CORT have crossed above the average analyst 12 month target price of 12 25 changing hands for 12 47 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
CORT,CORT:US,BBG000BKJG33,"Ingalls & Snyder Llc Buys General Electric Co, Delta Air Lines Inc, JPMorgan Chase, Sells ...",2017-07-29 10:56:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3eybb3BmoiA/ingalls-snyder-llc-buys-general-electric-co-delta-air-lines-inc-jpmorgan-chase-sells-cm823765,Ingalls Snyder Llc New Purchases USAS EXC BUD OXY NVDA SWM RTN HAIN GIII SNH Added Positions GE DAL JPM C DRRX EMR GS WFC CNQ CSCO Reduced Positions CORT UTX CPRT GTY UL HXL WMB ORCL SSB KMB Sold Out BRK B AAPL ABT
CORT,CORT:US,BBG000BKJG33,3 Under-the-Radar Stocks in the Healthcare Sector,2017-07-26 14:00:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VBMUiILlmI4/3-under-the-radar-stocks-in-the-healthcare-sector-cm821449,While large cap stocks tend to grab more of the headlines there s a whole universe of small cap companies out there to consider as well But which of those lesser known companies are most deserving of a closer look for your portfolio To help answer that question and to narrow it
CORT,CORT:US,BBG000BKJG33,3 Under-the-Radar Stocks in the Healthcare Sector,2017-07-26 12:08:00 +0000,http://finance.yahoo.com/r/0596d048-db53-37ce-91ab-92e09f4d02a6/3-under-the-radar-stocks-in-the-healthcare-sector.aspx?yptr=yahoo&.tsrc=rss,"Syndax Pharmaceuticals, Corcept Therapeutics,Â and LeMaitre Vascular might not be household names, but they are companies investors should get to know."
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call",2017-07-25 20:05:00 +0000,https://finance.yahoo.com/news/corcept-therapeutics-announce-second-quarter-200500096.html?.tsrc=rss,"MENLO PARK, Calif., July 25, 2017-- Corcept Therapeutics Incorporated today announced it will report its second quarter 2017 financial results and provide a corporate update on August 1, 2017. The Company ..."
CORT,CORT:US,BBG000BKJG33,Vertex (VRTX) Triple Combination CF Studies Data Positive,2017-07-19 16:06:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i5oT8kavhNc/vertex-vrtx-triple-combination-cf-studies-data-positive-cm818097,Vertex Pharmaceuticals Incorporated VRTX announced data from three studies wherein three different triple combination regimens were evaluated for the treatment of cystic fibrosis CF These led to pronounced improvements in lung function Shares of the company surged more than 25 in after
CORT,CORT:US,BBG000BKJG33,Is It Too Late to Get In on This Millionaire-Maker Stock?,2017-07-16 12:45:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qk6Tu3lmlOQ/is-it-too-late-to-get-in-on-this-millionaire-maker-stock-cm816577,Corcept Therapeutics NASDAQ CORT is one hot biotech stock no matter how you look at it Shares have nearly quintupled in value in just three years So far in 2017 Corcept stock is up around 70 Those kinds of returns could make millionaires out of some investors if the
CORT,CORT:US,BBG000BKJG33,Is It Too Late to Get In on This Millionaire-Maker Stock?,2017-07-16 10:42:00 +0000,http://finance.yahoo.com/r/bbcbe128-3dc2-36de-a0b4-83fb4b50a198/is-it-too-late-to-get-in-on-this-millionaire-maker.aspx?yptr=yahoo&.tsrc=rss,"Corcept Therapeutics stock has skyrocketed, but are the biggest moves already over?"
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Focuses on Korlym's Label Expansion,2017-07-13 23:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c6fMnVA1mE0/corcept-therapeutics-focuses-on-korlyms-label-expansion-cm815921,We issued an updated research report on Corcept Therapeutics Inc CORT on Jul 12 Corcept s shares have surged 71 2 year to date comparing favorably with the Zacks classified Medical Drugs industry s gain of 6 3 Currently the company is striving to commercialize
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Focuses on Korlym&apos;s Label Expansion,2017-07-13 21:44:09 +0000,https://finance.yahoo.com/news/corcept-therapeutics-focuses-korlym-apos-214409176.html?.tsrc=rss,We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.
CORT,CORT:US,BBG000BKJG33,"ETFs with exposure to Corcept Therapeutics, Inc. : July 12, 2017",2017-07-12 18:23:43 +0000,http://finance.yahoo.com/r/75a9a1a4-4072-3bd8-8a7c-1d2b87f08d39/etfs-with-exposure-to-corcept-therapeutics-inc-july-12-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Why is Corcept's Stock Up More Than 60% So Far This Year?,2017-07-03 15:49:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/afkyr86r2fw/why-is-corcepts-stock-up-more-than-60-so-far-this-year-cm811198,Shares of Corcept Therapeutics Incorporated CORT has soared 62 5 this year so far massively outperforming the 5 6 increase registered by the Zacks classified Medical Drugs industry during this period Here we analyze the factors that led to the rally Corcept s only marketed
CORT,CORT:US,BBG000BKJG33,Why is Corcept&apos;s Stock Up More Than 60% So Far This Year?,2017-07-03 13:50:01 +0000,https://finance.yahoo.com/news/why-corcept-apos-stock-more-135001354.html?.tsrc=rss,"Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period."
CORT,CORT:US,BBG000BKJG33,"ETFs with exposure to Corcept Therapeutics, Inc. : June 30, 2017",2017-06-30 18:49:12 +0000,http://finance.yahoo.com/r/aee87e70-9e9b-35c0-9e24-34efa0f46955/etfs-with-exposure-to-corcept-therapeutics-inc-june-30-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Incorporated in 3 Charts,2017-06-26 13:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KD-1dpbut-Y/corcept-therapeutics-incorporated-in-3-charts-cm807952,Corcept Therapeutics Incorporated NASDAQ CORT is definitely on a roll The drugmaker s stock is up nearly 70 so far in 2017 Corcept s share price has has more than doubled over the past 12 months And over the last three years the company s market cap has nearly quadrupled What
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Incorporated in 3 Charts,2017-06-26 12:43:00 +0000,http://finance.yahoo.com/r/3a399a59-8811-3f8c-aead-e4ff77624b12/corcept-therapeutics-incorporated-in-3-charts.aspx?yptr=yahoo&.tsrc=rss,Corcept has been one of the best-performing drug stocks this year. These charts show why the good times could continue.
CORT,CORT:US,BBG000BKJG33,"ETFs with exposure to Corcept Therapeutics, Inc. : June 19, 2017",2017-06-19 19:06:32 +0000,http://finance.yahoo.com/r/848e2438-bc1a-3fb2-b3bb-7e1e20c3a1d2/etfs-with-exposure-to-corcept-therapeutics-inc-june-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017",2017-06-16 16:11:21 +0000,http://finance.yahoo.com/r/eca2f803-012e-3f40-9301-f9a4629925b9/corcept-therapeutics-inc-cort-us-earnings-analysis-q1-2017-by-the-numbers-june-16-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Corcept Therapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Corcept Therapeutics, Inc. â€“ Catalyst Biosciences, Inc., Johnson & Johnson, Impax Laboratories, Inc., Pfizer Inc., Novartis AG Sponsored ADR, Mylan N.V., Bristol-Myers Squibb Company, Eli Lilly and Company, ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Plains GP Holdings LP (PAGP) and Green Plains Inc (GPRE) Lead Todayâ€™s Top 11 Investor Filings,2017-06-15 15:11:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oJdA2VMaZAY/plains-gp-holdings-lp-pagp-and-green-plains-inc-gpre-lead-todays-top-11-investor-filings-cm803912,InvestorPlace Stock Market News Stock Advice amp Trading Tips There were 11 notable investor filings today Plains GP Holdings LP NYSE PAGP is the largest company of interest When a person or group of persons acquires beneficial ownership
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : June 15, 2017",2017-06-15 12:32:01 +0000,http://finance.yahoo.com/r/65d2c43f-e284-3977-94e6-6ef2a8a06d1a/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-cort-us-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous dayâ€™s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corcept Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Pharma Stock With Triple-Digit Growth Forming Blotchy Base,2017-05-24 16:12:29 +0000,http://finance.yahoo.com/r/0e418fb8-7630-3ea6-a905-2acc4feabed0/pharma-stock-with-triple-digit-growth-forming-blotchy-base?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Ionis Pharmaceuticals shows improving technical performance. Will it continue?
CORT,CORT:US,BBG000BKJG33,"ETFs with exposure to Corcept Therapeutics, Inc. : May 18, 2017",2017-05-18 17:37:26 +0000,http://finance.yahoo.com/r/79df1b5b-4e65-3a27-83e6-cfb9fc1bb84a/etfs-with-exposure-to-corcept-therapeutics-inc-may-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate,2017-05-12 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-synthetic-biologics-wins-121500826.html?.tsrc=rss,"Upcoming AWS Coverage on Corcept Therapeutics Post-Earnings Results LONDON, UK / ACCESSWIRE / May 12, 2017 / Active Wall St. blog coverage looks at the headline from Synthetic Biologics, Inc. (NYSE: SYN ..."
CORT,CORT:US,BBG000BKJG33,4 of the Cheapest Biotech Stocks in the World,2017-05-11 16:06:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x2RV_FePCyg/4-of-the-cheapest-biotech-stocks-in-the-world-cm788001,When you think of biotech stocks cheap is probably the last word that comes to mind Most biotech stocks aren t profitable and many have no products currently on pharmacy shelves This means biotech valuations tend to be a hodgepodge of investor emotions future peak
CORT,CORT:US,BBG000BKJG33,4 of the Cheapest Biotech Stocks in the World,2017-05-11 04:00:00 +0000,http://finance.yahoo.com/r/c2084956-a67d-3e34-b06d-4378c34488a1/4-of-the-cheapest-biotech-stocks-in-the-world.aspx?yptr=yahoo&.tsrc=rss,All four of these drug stocks have PEG ratios below 1.
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : May 10, 2017",2017-05-10 12:17:07 +0000,http://finance.yahoo.com/r/83517a68-0d34-3bc3-9dd7-555a9be9faf5/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-cort-us-may-10-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous dayâ€™s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corcept Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Edited Transcript of CORT earnings conference call or presentation 1-May-17 9:00pm GMT,2017-05-04 12:40:46 +0000,http://finance.yahoo.com/news/edited-transcript-cort-earnings-conference-123338244.html?.tsrc=rss,Q1 2017 Corcept Therapeutics Inc Earnings Call
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress,2017-05-04 12:30:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announces-presentations-mifepristone-123000548.html?.tsrc=rss,"Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating ..."
CORT,CORT:US,BBG000BKJG33,"AZN Gets FDA Nod, CORT Boosts Outlook Yet Again, SNSS Withdraws Vosaroxin MAA",2017-05-02 02:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMnny--GAp4/azn-gets-fda-nod-cort-boosts-outlook-yet-again-snss-withdraws-vosaroxin-maa-20170502-00059,"AZN Gets FDA Nod, CORT Boosts Outlook Yet Again, SNSS Withdraws Vosaroxin MAA"
CORT,CORT:US,BBG000BKJG33,Corcept posts 1Q profit,2017-05-01 21:01:06 +0000,http://finance.yahoo.com/news/corcept-posts-1q-profit-210106323.html?.tsrc=rss,"On a per-share basis, the Menlo Park, California-based company said it had profit of 4 cents. The drug developer posted revenue of $27.6 million in the period. Corcept expects full-year revenue in the ..."
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update",2017-05-01 20:05:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announces-first-quarter-200500533.html?.tsrc=rss,Corcept Therapeutics Incorporated
CORT,CORT:US,BBG000BKJG33,Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call,2017-05-01 15:10:00 +0000,http://finance.yahoo.com/news/investor-network-corcept-therapeutics-incorporated-151000464.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 1, 2017 / Corcept Therapeutics Incorporated. (NASDAQ: CORT) will be discussing their earnings results in their Q1 Earnings Call to be held May 1, 2017 at 5:00 PM Eastern ..."
CORT,CORT:US,BBG000BKJG33,"Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View",2017-04-27 17:31:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UvB3_DUBab0/bristol-myers-bmy-beats-on-q1-earnings-ups-2017-view-cm780504,Bristol Myers Squibb Company s BMY first quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14 from the year ago period We note that the bottom line was boosted by an 18 cent contribution from the patent infringement litigation settlement
CORT,CORT:US,BBG000BKJG33,"Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View",2017-04-27 15:01:03 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-beats-q1-150103081.html?.tsrc=rss,Bristol-Myers Squibb Company&apos;s (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : April 25, 2017",2017-04-25 20:09:55 +0000,http://finance.yahoo.com/r/40d4c122-4766-3bc6-82fb-c7cdfae8b6de/corcept-therapeutics-inc-value-analysis-nasdaqcort-april-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Corcept Therapeutics, Inc. a score of 69. Our analysis is based on comparing Corcept Therapeutics, Inc. with the following peers â€“ Catalyst Biosciences, Inc., Johnson & Johnson, Impax Laboratories, Inc., Pfizer Inc., Novartis AG Sponsored ADR, Mylan N.V., Bristol-Myers Squibb Company, Eli Lilly and Company, Esperion Therapeutics, ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call,2017-04-24 20:05:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announce-first-quarter-200500152.html?.tsrc=rss,"Corcept Therapeutics Incorporated today announced it will report first quarter financial results and provide a corporate update on May 1, 2017. The Company will also host a conference call that day at ..."
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : April 24, 2017",2017-04-24 12:42:19 +0000,http://finance.yahoo.com/r/ccba3241-a31a-339e-a343-4ae059224c4b/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-cort-us-april-24-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous dayâ€™s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corcept Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Here's Why Corecept Therapeutics Incorporated Had a Rough Day,2017-04-22 00:02:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5OI1dZQ2D_U/heres-why-corecept-therapeutics-incorporated-had-a-rough-day-cm777409,What happened Shares of Corcept Therapeutics Incorporated NASDAQ CORT a company focused on developing drugs for the treatment of a variety of cortisol hormone related disorders finished the week down about 14 2 after an 8 8 slide in Friday s session A solid fourth
CORT,CORT:US,BBG000BKJG33,7 Healthcare Stocks With A-Rated Prospects,2017-04-21 23:03:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RE0mtOFARI0/7-healthcare-stocks-with-a-rated-prospects-cm777414,InvestorPlace Stock Market News Stock Advice amp Trading Tips For President Donald Trump s 100 day anniversary it looks like Congressional Republicans are trying to give him a present they couldn t muster earlier in his term healthcare reform of the Affordable Care Act aka
CORT,CORT:US,BBG000BKJG33,Here&apos;s Why Corecept Therapeutics Incorporated Had a Rough Day,2017-04-21 22:24:00 +0000,http://finance.yahoo.com/r/614a7829-f2b7-339b-a073-9437cb245d6c/corecept-therapeutics-incorporated-skidded-today-c.aspx?yptr=yahoo&.tsrc=rss,"Korlym&apos;s driving growth now, but investors would like to see more drugs in development."
CORT,CORT:US,BBG000BKJG33,Nivalis' (NVLS) Shares Down After Merger Deal with Alpine,2017-04-20 17:05:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EKnvaJtcNb0/nivalis-nvls-shares-down-after-merger-deal-with-alpine-cm776519,The announcement of Nivalis Therapeutics Inc s NVLS merger agreement with a privately held biotechnology company Alpine Immune Sciences Inc failed to excite investors Nivalis fell more than 10 on Wednesday following the announcement This all stock transaction is expected to be
CORT,CORT:US,BBG000BKJG33,Nivalis&apos; (NVLS) Shares Down After Merger Deal with Alpine,2017-04-20 14:30:02 +0000,http://finance.yahoo.com/news/nivalis-apos-nvls-shares-down-143002400.html?.tsrc=rss,"The announcement of Nivalis Therapeutics, Inc.&apos;s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors."
CORT,CORT:US,BBG000BKJG33,AMAG Files for FDA Approval of Subcutaneous Form of Makena,2017-04-18 17:05:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nqXnlP1MjDM/amag-files-for-fda-approval-of-subcutaneous-form-of-makena-cm775338,AMAG Pharmaceuticals Inc AMAG announced the submission of a supplemental New Drug Application sNDA to the FDA for the subcutaneous auto injector form of its marketed drug Makena in the U S 160 Makena is currently approved as an intramuscular IM injection to reduce the risk of
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?,2017-04-06 12:56:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2hj2YUP4rHo/corcept-cort-up-18-since-earnings-report-can-it-continue-cm770581,A month has gone by since the last earnings report for Corcept Therapeutics Incorporated CORT Shares have added about 18 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?,2017-04-06 11:00:11 +0000,http://finance.yahoo.com/news/corcept-cort-18-since-earnings-110011176.html?.tsrc=rss,Corcept (CORT) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
CORT,CORT:US,BBG000BKJG33,No. 5-Ranked Biotech Bolts Higher On Drug Results,2017-03-30 15:03:36 +0000,http://www.investors.com/ibd-data-stories/no-5-ranked-biotech-bolts-higher-on-drug-results/?src=A00220A,No. 5-Ranked Biotech Bolts Higher On Drug Results
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Strives to Commercialize Key Drug Korlym,2017-03-29 22:59:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uNjz3eALwxI/corcept-cort-strives-to-commercialize-key-drug-korlym-cm767513,We issued an updated report on Corcept Therapeutics Inc CORT on Mar 28 Corcept s share price shows that the company has outperformed the Zacks classified Medical Drugs industry year to date The stock gained 54 as compared to the industry s gain of 5 3 Korlym is Corcept s lead
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Strives to Commercialize Key Drug Korlym,2017-03-29 20:51:08 +0000,http://finance.yahoo.com/news/corcept-cort-strives-commercialize-key-205108231.html?.tsrc=rss,We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Strives to Commercialize Key Drug Korlym,2017-03-29 20:51:08 +0000,http://finance.yahoo.com/news/corcept-cort-strives-commercialize-key-205108231.html,Corcept (CORT) Strives to Commercialize Key Drug Korlym
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutices Eyes Another Double,2017-03-20 19:03:00 +0000,http://realmoney.thestreet.com/articles/03/20/2017/corcept-therapeutices-eyes-another-double?puc=yahoo&cm_ven=YAHOO,Corcept Therapeutices Eyes Another Double
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutices Eyes Another Double,2017-03-20 19:03:00 +0000,http://finance.yahoo.com/r/27d1bea9-c3ae-3ae7-91df-3298877df6ea/corcept-therapeutices-eyes-another-double?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Biotech has a base pattern than can support a lot more upside..
CORT,CORT:US,BBG000BKJG33,Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics,2017-03-17 13:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-stocks-watch-133000015.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Array Biopharma and Corcept Therapeutics are two companies whose stock prices both fell on Thursday, following the trend of the general market. Both stocks ..."
CORT,CORT:US,BBG000BKJG33,Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics,2017-03-17 13:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-stocks-watch-133000015.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Array Biopharma and Corcept Therapeutics are two companies whose stock prices both fell on Thursday, following the trend of the general market. Both stocks ..."
CORT,CORT:US,BBG000BKJG33,Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging',2017-03-10 21:39:34 +0000,http://finance.yahoo.com/r/da47121d-4b84-3622-a24e-8033508648f0/biotech-stock-corcept-encouraging-breast-cancer-trial-results-near-breakout?src=A00220A&yptr=yahoo&.tsrc=rss,"In addition to big-name biotech stocks like Amgen and Celgene, investors should also keep an eye on lesser-known, but highly-rated and fast-growing Corcept Therapeutics."
CORT,CORT:US,BBG000BKJG33,Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging',2017-03-10 21:39:34 +0000,http://www.investors.com/research/ibd-stock-analysis/biotech-stock-corcept-encouraging-breast-cancer-trial-results-near-breakout/?src=A00220A,Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging'
CORT,CORT:US,BBG000BKJG33,CORCEPT THERAPEUTICS INC Financials,2017-03-10 18:04:07 +0000,http://finance.yahoo.com/q/is?s=cort,CORCEPT THERAPEUTICS INC Financials
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017",2017-03-07 17:15:07 +0000,http://finance.yahoo.com/r/cb04cbec-41ae-3a8d-b0c2-878f29201998/corcept-therapeutics-inc-cort-us-earnings-analysis-q4-2016-by-the-numbers-march-7-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Corcept Therapeutics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Corcept Therapeutics, Inc. â€“ Johnson & Johnson, Impax Laboratories, Inc., Pfizer Inc., Novartis AG Sponsored ADR, Mylan N.V., Bristol-Myers Squibb Company, Eli Lilly and Company and Esperion Therapeutics, ... Read more    
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017",2017-03-07 17:15:07 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-cort-us-earnings-analysis-q4-2016-by-the-numbers-march-7-2017/,"Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017"
CORT,CORT:US,BBG000BKJG33,"Health Care Sector Update for 03/06/2017: CORT,TGTX,IONS",2017-03-06 19:52:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ITdr3xT_H38/health-care-sector-update-for-03062017-corttgtxions-cm756832,Top Health Care StocksTop Health Care Stocks JNJ 0 41 JNJ 0 41 PFE 0 25 PFE 0 25 MRK 0 18 MRK 0 18 ABT 0 10 ABT 0 10 AMGN 0 24 AMGN 0 24 Health care stocks still were slightly lower this afternoon reversing earlier declines with the NYSE Health Care Index posting a 0 3
CORT,CORT:US,BBG000BKJG33,Corcept beats 4Q profit forecasts,2017-03-06 13:44:26 +0000,http://sg.finance.yahoo.com/news/corcept-beats-4q-profit-forecasts-134426733.html,Corcept beats 4Q profit forecasts
CORT,CORT:US,BBG000BKJG33,Corcept beats 4Q profit forecasts,2017-03-06 13:44:26 +0000,http://finance.yahoo.com/news/corcept-beats-4q-profit-forecasts-134426164.html?.tsrc=rss,"On a per-share basis, the Menlo Park, California-based company said it had profit of 4 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 6 cents per share. The results surpassed ..."
CORT,CORT:US,BBG000BKJG33,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure",2017-03-06 13:37:35 +0000,http://biz.yahoo.com/e/170306/cort8-k.html,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure"
CORT,CORT:US,BBG000BKJG33,8:36 am Corcept Therapeutics reports Q4 results; raises FY17 rev guidance,2017-03-06 13:36:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#cort,8:36 am Corcept Therapeutics reports Q4 results; raises FY17 rev guidance
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance,2017-03-06 13:30:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announces-fourth-quarter-133000371.html?.tsrc=rss,Corcept Therapeutics Incorporated
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance,2017-03-06 13:30:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announces-fourth-quarter-133000371.html,[Marketwired] - Corcept Therapeutics Incorporated
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : February 14, 2017",2017-02-14 18:56:45 +0000,http://finance.yahoo.com/r/f2293079-5949-3934-9db3-41eaa3d7bed2/corcept-therapeutics-inc-value-analysis-nasdaqcort-february-14-2017?yptr=yahoo&.tsrc=rss,"Categories:   Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Corcept Therapeutics, Inc. a score of 66. Our analysis is based on comparing Corcept Therapeutics, Inc. with the following peers â€“ Catalyst Biosciences, Inc., Johnson & Johnson, Impax Laboratories, Inc., Pfizer Inc., Novartis AG Sponsored ADR, Mylan N.V., Bristol-Myers Squibb Company, Eli Lilly and Company, Esperion Therapeutics, ... Read more    
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : February 14, 2017",2017-02-14 18:56:45 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-value-analysis-nasdaqcort-february-14-2017/,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : February 14, 2017"
CORT,CORT:US,BBG000BKJG33,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financi",2017-02-13 21:19:38 +0000,http://biz.yahoo.com/e/170213/cort8-k.html,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financi"
CORT,CORT:US,BBG000BKJG33,Coverage initiated on Corcept Therapeutics by Ladenburg Thalmann,2017-02-02 12:23:06 +0000,http://finance.yahoo.com/q/ud?s=CORT,Coverage initiated on Corcept Therapeutics by Ladenburg Thalmann
CORT,CORT:US,BBG000BKJG33,"Health Care Sector Update for 01/31/2017: CORT,AEZS,TENX",2017-01-31 18:51:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IyBN8U8XwSk/health-care-sector-update-for-01312017-cortaezstenx-cm741038,Top Health Care StocksTop Health Care Stocks JNJ 0 19 JNJ 0 19 PFE 0 37 PFE 0 37 MRK 0 71 MRK 0 71 ABT 0 61 ABT 0 61 AMGN 0 32 AMGN 0 32 Health care stocks were mostly higher Tuesday after the White House promised less regulation and more competition for drugmakers during a
CORT,CORT:US,BBG000BKJG33,Edited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT,2017-01-31 07:14:14 +0000,http://finance.yahoo.com/news/edited-transcript-cort-earnings-conference-071414294.html,Edited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT
CORT,CORT:US,BBG000BKJG33,Edited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT,2017-01-31 07:14:14 +0000,http://finance.yahoo.com/news/edited-transcript-cort-earnings-conference-071414294.html?.tsrc=rss,Preliminary Q4 2016 Corcept Therapeutics Inc Earnings Call
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance,2017-01-30 21:05:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announces-preliminary-fourth-210500739.html,[Marketwired] - Corcept Therapeutics Incorporated
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance,2017-01-30 21:05:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announces-preliminary-fourth-210500739.html?.tsrc=rss,Corcept Therapeutics Incorporated
CORT,CORT:US,BBG000BKJG33,Preliminary Q4 2016 Corcept Therapeutics Inc Earnings Release - After Market Close,2017-01-30 12:07:02 +0000,http://biz.yahoo.com/research/earncal/20170130.html?t=cort,Preliminary Q4 2016 Corcept Therapeutics Inc Earnings Release - After Market Close
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call",2017-01-23 21:05:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announce-preliminary-2016-210500006.html?.tsrc=rss,"Corcept Therapeutics Incorporated today announced it will report preliminary fourth quarter and full year 2016 financial results and provide 2017 revenue guidance and a corporate update on January 30, ..."
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call",2017-01-23 21:05:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announce-preliminary-2016-210500006.html,"[Marketwired] - Corcept Therapeutics Incorporated today announced it will report preliminary fourth quarter and full year 2016 financial results and provide 2017 revenue guidance and a corporate update on January 30, ..."
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : January 11, 2017",2017-01-11 12:26:20 +0000,http://finance.yahoo.com/r/dab5e11b-815d-3117-afcb-7d3bc7e15716/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-cort-us-january-11-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous dayâ€™s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corcept Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : January 11, 2017",2017-01-11 12:26:20 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-cort-us-january-11-2017/,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : January 11, 2017"
CORT,CORT:US,BBG000BKJG33,3 Stocks Expected to More Than Double Their Earnings in 2017,2017-01-09 12:25:11 +0000,http://finance.yahoo.com/r/957e41d6-8604-37c4-a2f6-2badaa93e05c/3-stocks-expected-to-more-than-double-their-earnin.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo&.tsrc=rss,"Wall Street has high expectations in the coming year for Corcept Therapeutics, Incyte, and Exelixis."
CORT,CORT:US,BBG000BKJG33,3 Stocks Expected to More Than Double Their Earnings in 2017,2017-01-09 12:25:11 +0000,http://www.fool.com/investing/2017/01/08/3-stocks-expected-to-more-than-double-their-earnin.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks Expected to More Than Double Their Earnings in 2017
CORT,CORT:US,BBG000BKJG33,3 Stocks Expected to More Than Double Their Earnings in 2017,2017-01-08 13:49:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gmYAYq0nPTo/3-stocks-expected-to-more-than-double-their-earnings-in-2017-cm730785,Most investors idea of impressive earnings growth is say 20 or more per year So what does that say about companies that grow their earnings by more than 100 in a year That s what Wall Street expects three biotechs to achieve over the next year Here s how Corcept
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : December 23, 2016",2016-12-23 14:23:44 +0000,http://finance.yahoo.com/r/08da51e3-7fef-3f82-b82f-df73311891b6/corcept-therapeutics-inc-value-analysis-nasdaqcort-december-23-2016?yptr=yahoo&.tsrc=rss,"Categories:   Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Corcept Therapeutics, Inc. a score of 66. Our analysis is based on comparing Corcept Therapeutics, Inc. with the following peers â€“ Catalyst Biosciences, Inc., Johnson & Johnson, Impax Laboratories, Inc., Pfizer Inc., Novartis AG Sponsored ADR, Mylan N.V., Bristol-Myers Squibb Company, Eli Lilly and Company, Esperion Therapeutics, ... Read more    
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : December 23, 2016",2016-12-23 14:23:44 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-value-analysis-nasdaqcort-december-23-2016/,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : December 23, 2016"
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : December 22, 2016",2016-12-22 12:26:10 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-cort-us-december-22-2016/,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : December 22, 2016"
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : December 22, 2016",2016-12-22 12:26:10 +0000,http://finance.yahoo.com/r/756b2614-2758-3fe6-b22c-ff9669e1f9bf/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-cort-us-december-22-2016?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous dayâ€™s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corcept Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
CORT,CORT:US,BBG000BKJG33,Mid-Day Market Update: Conatus Jumps Following Announcement of Licensing Deal With Novartis; Sucampo Shares Slide,2016-12-20 18:37:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LsPUfaLikKo/mid-day-market-update-conatus-jumps-following-announcement-of-licensing-deal-with-novartis-sucampo-shares-slide-cm724165,Midway through trading Tuesday the Dow traded up 0 43 percent to 19 968 82 while the NASDAQ rose 0 48 percent to 5 483 49 The S amp P also rose gaining 0 39 percent to 2 271 34 Leading and Lagging Sectors Cyclical consumer goods amp services shares gained around 0 64 percent
CORT,CORT:US,BBG000BKJG33,Corcept Korlym Positive in Phase I/II Breast Cancer Study,2016-12-12 16:58:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4q8YaJiRM0U/corcept-korlym-positive-in-phase-iii-breast-cancer-study-cm720125,Corcept Therapeutics Incorporated CORT announced encouraging efficacy data from a phase I II study on Korlym mifepristone in patients suffering from metastatic triple negative breast cancer TNBC Data were presented at the San Antonio Breast Cancer Symposium Corcept s year to date
CORT,CORT:US,BBG000BKJG33,Corcept Korlym Positive in Phase I/II Breast Cancer Study,2016-12-12 14:54:02 +0000,http://finance.yahoo.com/news/corcept-korlym-positive-phase-ii-145402403.html?.tsrc=rss,Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.
CORT,CORT:US,BBG000BKJG33,Corcept Korlym Positive in Phase I/II Breast Cancer Study,2016-12-12 14:54:02 +0000,http://finance.yahoo.com/news/corcept-korlym-positive-phase-ii-145402403.html,Corcept Korlym Positive in Phase I/II Breast Cancer Study
CORT,CORT:US,BBG000BKJG33,Should You Add Corcept Therapeutics Incorporated (CORT) To Your Portfolio?,2016-12-11 02:37:44 +0000,http://www.insidermonkey.com/blog/should-you-add-corcept-therapeutics-incorporated-cort-to-your-portfolio-505220/,Should You Add Corcept Therapeutics Incorporated (CORT) To Your Portfolio?
CORT,CORT:US,BBG000BKJG33,Should You Add Corcept Therapeutics Incorporated (CORT) To Your Portfolio?,2016-12-11 02:37:44 +0000,http://finance.yahoo.com/r/82e15393-ad41-3158-b013-82f9da178ac1/should-you-add-corcept-therapeutics-incorporated-cort-to-your-portfolio-505220?yptr=yahoo&.tsrc=rss,"Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players [â€¦]"
CORT,CORT:US,BBG000BKJG33,Corcept: Mifepristone Plus Eribulin Phase 1/2 Trial Trial Results Encouraging,2016-12-10 20:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dB056H5iVn4/corcept-mifepristone-plus-eribulin-phase-12-trial-trial-results-encouraging-20161210-00034,Corcept: Mifepristone Plus Eribulin Phase 1/2 Trial Trial Results Encouraging
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer,2016-12-10 13:30:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announces-encouraging-results-133000913.html?.tsrc=rss,"Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating ..."
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer,2016-12-10 13:30:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-announces-encouraging-results-133000913.html,"[Marketwired] - Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating ..."
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Looks Good: Stock Jumps 6.5% in Session,2016-11-11 15:15:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5BWU08M-RBQ/corcept-cort-looks-good-stock-jumps-65-in-session-cm707685,Corcept Therapeutics Incorporated CORT was a big mover last session as the company saw its shares rise over 6 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Looks Good: Stock Jumps 6.5% in Session,2016-11-11 13:35:01 +0000,http://finance.yahoo.com/news/corcept-cort-looks-good-stock-133501472.html?.tsrc=rss,"Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise over 6% on the day."
CORT,CORT:US,BBG000BKJG33,Corcept (CORT) Looks Good: Stock Jumps 6.5% in Session,2016-11-11 13:35:01 +0000,http://finance.yahoo.com/news/corcept-cort-looks-good-stock-133501472.html,Corcept (CORT) Looks Good: Stock Jumps 6.5% in Session
CORT,CORT:US,BBG000BKJG33,"Corcept (CORT) Beats on Q3 Earnings, Lifts Sales Guidance",2016-11-02 13:16:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B-jeXkaeGNc/corcept-cort-beats-on-q3-earnings-lifts-sales-guidance-cm702305,Corcept Therapeutics Incorporated s CORT adjusted third quarter 2016 earnings including stock based compensation expense of 2 cents per share beating the Zacks Consensus Estimate of a penny Excluding stock based compensation expenses adjusted earnings amounted to 4 cents per
CORT,CORT:US,BBG000BKJG33,"Corcept (CORT) Beats on Q3 Earnings, Lifts Sales Guidance",2016-11-02 12:12:12 +0000,http://finance.yahoo.com/news/corcept-cort-beats-q3-earnings-121212353.html,"Corcept (CORT) Beats on Q3 Earnings, Lifts Sales Guidance"
CORT,CORT:US,BBG000BKJG33,"CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report",2016-11-02 10:08:24 +0000,http://biz.yahoo.com/e/161102/cort10-q.html,"CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report"
CORT,CORT:US,BBG000BKJG33,Edited Transcript of CORT earnings conference call or presentation 1-Nov-16 9:00pm GMT,2016-11-02 09:02:33 +0000,http://finance.yahoo.com/news/edited-transcript-cort-earnings-conference-090233863.html,Edited Transcript of CORT earnings conference call or presentation 1-Nov-16 9:00pm GMT
CORT,CORT:US,BBG000BKJG33,Corcept beats 3Q profit forecasts,2016-11-01 21:40:12 +0000,http://sg.finance.yahoo.com/news/corcept-beats-3q-profit-forecasts-214012590.html,Corcept beats 3Q profit forecasts
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update,2016-11-01 21:00:12 +0000,http://www.publicnow.com/view/1845D539844073BAD11F66F3EC2D2A035DAF5D05,"[at noodls] - Download this Press Release Financial Highlights Third quarter revenue of $21.7 million, a 64 percent increase from the third quarter of 2015 Third quarter GAAP net income of $0.02 per share, ..."
CORT,CORT:US,BBG000BKJG33,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure",2016-11-01 20:11:57 +0000,http://biz.yahoo.com/e/161101/cort8-k.html,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure"
CORT,CORT:US,BBG000BKJG33,Q3 2016 Corcept Therapeutics Inc Earnings Release - After Market Close,2016-11-01 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20161101.html?t=cort,Q3 2016 Corcept Therapeutics Inc Earnings Release - After Market Close
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics to Announce Third Quarter 2016 Financial Results and Corporate Update and Host Conference Call,2016-10-26 15:45:06 +0000,http://www.publicnow.com/view/767BDCE83C8EAF7D69DD4263E5454F42DD84BF2B,"[at noodls] - Download this Press Release Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 1, 2016. ..."
CORT,CORT:US,BBG000BKJG33,Emergent (EBS) Stock Up on Multi-Year NuThrax Vaccine Deal,2016-10-03 16:45:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LBxnRBAyV08/emergent-ebs-stock-up-on-multi-year-nuthrax-vaccine-deal-cm687825,Emergent BioSolutions Inc s EBS shares jumped 13 6 after the company announced that it has secured a multi year contract worth about 1 6 billion with the Biomedical Advanced Research and Development Authority BARDA for the advanced development and delivery of the company s next
CORT,CORT:US,BBG000BKJG33,Top 3 Growth Stocks Under $10,2016-09-29 20:20:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rct0ixIb2HA/top-3-growth-stocks-under-10-cm686753,Here at Zacks we don t generally classify stocks as cheap or expensive and rather than looking at the stock s face value we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors That being said low priced stocks
CORT,CORT:US,BBG000BKJG33,Top 3 Growth Stocks Under $10,2016-09-29 18:13:06 +0000,http://finance.yahoo.com/news/top-3-growth-stocks-under-181306939.html,Top 3 Growth Stocks Under $10
CORT,CORT:US,BBG000BKJG33,Ionis/Biogen Complete Nusinersen NDA Submission in U.S.,2016-09-27 16:25:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lIVWqGO71Iw/ionisbiogen-complete-nusinersen-nda-submission-in-us-cm685388,Ionis Pharmaceuticals Inc IONS announced that its partner Biogen Inc BIIB has completed the rolling submission of a New Drug Application NDA for nusinersen in the U S for the treatment of spinal muscular atrophy SMA In addition Biogen has requested the FDA for Priority Review of
CORT,CORT:US,BBG000BKJG33,Array (ARRY) Hits 52-Week High on Positive Phase III Data,2016-09-27 15:24:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fAmlk8KAmqk/array-arry-hits-52-week-high-on-positive-phase-iii-data-cm685278,Array BioPharma Inc ARRY along with its partner Pierre Fabre announced positive top line data from part 1 of the phase III study COLUMBUS on a combination of encorafenib BRAF inhibitor and binimetinib MEK inhibitor for the treatment of BRAF mutant advanced unresectable or
CORT,CORT:US,BBG000BKJG33,PAREXEL International (PRXL) Set to Acquire ExecuPharm,2016-09-27 15:23:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zoOg_DC5oN8/parexel-international-prxl-set-to-acquire-execupharm-cm685405,PAREXEL International Corporation PRXL a global biopharmaceutical services company and provider of clinical research and logistics recently announced the signing of a definitive agreement to acquire ExecuPharm Inc a King of Prussia PA based global functional service provider for
CORT,CORT:US,BBG000BKJG33,Ionis/Biogen Complete Nusinersen NDA Submission in U.S.,2016-09-27 14:12:02 +0000,http://finance.yahoo.com/news/ionis-biogen-complete-nusinersen-nda-141202017.html,Ionis/Biogen Complete Nusinersen NDA Submission in U.S.
CORT,CORT:US,BBG000BKJG33,PAREXEL International (PRXL) Set to Acquire ExecuPharm,2016-09-27 14:01:02 +0000,http://finance.yahoo.com/news/parexel-international-prxl-set-acquire-140102998.html,PAREXEL International (PRXL) Set to Acquire ExecuPharm
CORT,CORT:US,BBG000BKJG33,Array (ARRY) Hits 52-Week High on Positive Phase III Data,2016-09-27 13:42:01 +0000,http://finance.yahoo.com/news/array-arry-hits-52-week-134201633.html,Array (ARRY) Hits 52-Week High on Positive Phase III Data
CORT,CORT:US,BBG000BKJG33,Novartis Ilaris Approved for Extended Use in Periodic Fever,2016-09-26 15:25:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q7SPQXyy2YM/novartis-ilaris-approved-for-extended-use-in-periodic-fever-cm684463,Switzerland based Novartis AG NVS announced that its arthritis drug Ilaris was approved in the U S for expanded use in the treatment of three distinct types of periodic fever syndromes tumor necrosis factor receptor associated periodic syndrome TRAPS hyperimmunoglobulin
CORT,CORT:US,BBG000BKJG33,Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.,2016-09-26 14:23:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K9Ax-4UKSbk/glaxojj-file-bla-for-rheumatoid-arthritis-drug-in-the-us-cm684479,GlaxoSmithKline plc GSK and Johnson amp Johnson s JNJ Janssen Biotech Inc announced the submission of a Biologics License Application BLA for sirukumab for the treatment of adults with moderate to severely active rheumatoid arthritis RA The companies are seeking approval for
CORT,CORT:US,BBG000BKJG33,Novartis Ilaris Approved for Extended Use in Periodic Fever,2016-09-26 13:18:01 +0000,http://finance.yahoo.com/news/novartis-ilaris-approved-extended-periodic-131801541.html,Novartis Ilaris Approved for Extended Use in Periodic Fever
CORT,CORT:US,BBG000BKJG33,Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.,2016-09-26 12:56:12 +0000,http://finance.yahoo.com/news/glaxo-j-j-file-bla-125612704.html,Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.
CORT,CORT:US,BBG000BKJG33,"Edwards Lifesciences, DaVita HealthCare Partners, Corcept Therapeutics and CryoLife highlighted as Zacks Bull and Bear of the Day",2016-09-22 15:23:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2SlKaTorAKY/edwards-lifesciences-davita-healthcare-partners-corcept-therapeutics-and-cryolife-highlighted-as-zacks-bull-and-bear-of-the-day-cm683111,For Immediate Release Chicago IL September 22 2016 Zacks Equity Research highlights 160 Edwards Lifesciences EW as the Bull of the Day and DaVita HealthCare Partners DVA as the Bear of the Day In addition Zacks Equity Research provides analysis Corcept Therapeutics
CORT,CORT:US,BBG000BKJG33,"ETFâ€™s with exposure to Corcept Therapeutics, Inc. : September 22, 2016",2016-09-22 14:55:16 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-corcept-therapeutics-inc-september-22-2016/,"ETFâ€™s with exposure to Corcept Therapeutics, Inc. : September 22, 2016"
CORT,CORT:US,BBG000BKJG33,"Edwards Lifesciences, DaVita HealthCare Partners, Corcept Therapeutics and CryoLife highlighted as Zacks Bull and Bear of the Day",2016-09-22 13:30:01 +0000,http://finance.yahoo.com/news/edwards-lifesciences-davita-healthcare-partners-133001202.html,"Edwards Lifesciences, DaVita HealthCare Partners, Corcept Therapeutics and CryoLife highlighted as Zacks Bull and Bear of the Day"
CORT,CORT:US,BBG000BKJG33,Here are 2 Momentous Healthcare Stocks to Buy Now,2016-09-21 21:21:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PEyDpczRbxs/here-are-2-momentous-healthcare-stocks-to-buy-now-cm682868,Finding companies with the criteria you want isn t always easy 160 You could spend hours searching ticker after ticker only to find companies which aren t worthy of your hard earned cash 160 An easier way to navigate through this is by using 160 high quality stock screeners
CORT,CORT:US,BBG000BKJG33,Here are 2 Momentous Healthcare Stocks to Buy Now,2016-09-21 19:20:07 +0000,http://finance.yahoo.com/news/2-momentous-healthcare-stocks-buy-192007065.html,Here are 2 Momentous Healthcare Stocks to Buy Now
CORT,CORT:US,BBG000BKJG33,Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III,2016-09-21 16:24:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4uAw_HtqjCg/adamas-adms-parkinsons-disease-drug-positive-in-phase-iii-cm682698,Adamas Pharmaceuticals Inc ADMS announced positive data from the phase III study EASE LID 3 on its lead wholly owned candidate ADS 5102 extended release capsules for the treatment of levodopa induced dyskinesia LID associated with Parkinson s disease PD We expect investors to
CORT,CORT:US,BBG000BKJG33,New Strong Buy Stocks for September 21st,2016-09-21 15:25:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nQL1EvPSvtk/new-strong-buy-stocks-for-september-21st-cm682713,Here are 5 stocks added to the Zacks Rank 1 Strong Buy List today 160 160 160 Alliance Holdings GP L P AHGP This producer and seller of coal has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7 4 over the last 60 days ALLIANCE HLDGS
CORT,CORT:US,BBG000BKJG33,Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III,2016-09-21 14:28:02 +0000,http://finance.yahoo.com/news/adamas-adms-parkinsons-disease-drug-142802650.html,Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III
CORT,CORT:US,BBG000BKJG33,Aldeyra Therapeutics (ALDX) Worth a Look: Stock Gains 7%,2016-09-21 14:24:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hgM4KBbshgI/aldeyra-therapeutics-aldx-worth-a-look-stock-gains-7-cm682495,Aldeyra Therapeutics Inc ALDX was a big mover last session as the company saw its shares rise nearly 7 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above
CORT,CORT:US,BBG000BKJG33,Aldeyra Therapeutics (ALDX) Worth a Look: Stock Gains 7%,2016-09-21 12:45:12 +0000,http://finance.yahoo.com/news/aldeyra-therapeutics-aldx-worth-look-124512192.html,Aldeyra Therapeutics (ALDX) Worth a Look: Stock Gains 7%
CORT,CORT:US,BBG000BKJG33,New Strong Buy Stocks for September 21st,2016-09-21 12:37:12 +0000,http://finance.yahoo.com/news/strong-buy-stocks-september-21st-123712215.html,New Strong Buy Stocks for September 21st
CORT,CORT:US,BBG000BKJG33,Novartis (NVS) Presents Positive Data on Cardiovascular Drug,2016-09-19 16:24:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EC6p-TEQjh4/novartis-nvs-presents-positive-data-on-cardiovascular-drug-cm681339,Novartis AG NVS announces new analysis from the PARADIGM HF study on its cardiovascular drug Entresto at a scientific meeting of the Heart Failure Society of America Results from the study demonstrated the benefits of Entresto in heart failure patients with reduced ejection
CORT,CORT:US,BBG000BKJG33,Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab,2016-09-19 16:23:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cux0zgVfUvM/eli-lilly-lly-gets-favorable-chmp-opinion-for-olaratumab-cm681325,Eli Lilly and Company LLY announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has issued a positive opinion for a conditional marketing authorization of olaratumab in the treatment of advanced soft tissue sarcoma STS Eli Lilly
CORT,CORT:US,BBG000BKJG33,Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab,2016-09-19 14:25:02 +0000,http://finance.yahoo.com/news/eli-lilly-lly-gets-favorable-142502536.html,Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab
CORT,CORT:US,BBG000BKJG33,Advanced Accelerator (AAAP) Worth Watching: Stock Jumps 6.2%,2016-09-19 14:23:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zRGrfVzL7WQ/advanced-accelerator-aaap-worth-watching-stock-jumps-62-cm681175,Advanced Accelerator Applications S A AAAP was a big mover last session as the company saw its shares rise over 6 on the day Share gained after the company announced that the EMA has issued a positive opinion on the Marketing Authorization Application for SomaKit TOC 40Âµg for
CORT,CORT:US,BBG000BKJG33,Novartis (NVS) Presents Positive Data on Cardiovascular Drug,2016-09-19 14:16:02 +0000,http://finance.yahoo.com/news/novartis-nvs-presents-positive-data-141602423.html,Novartis (NVS) Presents Positive Data on Cardiovascular Drug
CORT,CORT:US,BBG000BKJG33,Should You Get Rid of Forward Pharma (FWP) Now?,2016-09-14 14:50:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q0kPtW82eS4/should-you-get-rid-of-forward-pharma-fwp-now-cm679348,Similar to wise buying decisions exiting certain underperformers at the right time helps maximize portfolio returns Selling off losers can be difficult but if both the share price and estimates are falling it could be time to get rid of the security before more losses hit your
CORT,CORT:US,BBG000BKJG33,Should You Get Rid of Forward Pharma (FWP) Now?,2016-09-14 12:39:12 +0000,http://finance.yahoo.com/news/rid-forward-pharma-fwp-now-123912459.html,Should You Get Rid of Forward Pharma (FWP) Now?
CORT,CORT:US,BBG000BKJG33,Nivalis Therapeutics (NVLS) Catches Eye: Stock Jumps 5.8%,2016-09-14 12:00:12 +0000,http://finance.yahoo.com/news/nivalis-therapeutics-nvls-catches-eye-120012238.html,Nivalis Therapeutics (NVLS) Catches Eye: Stock Jumps 5.8%
CORT,CORT:US,BBG000BKJG33,Geron (GERN) at 52-Week Low on Imetelstat Study Update,2016-09-13 15:48:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oZNlB5XnqiU/geron-gern-at-52-week-low-on-imetelstat-study-update-cm678759,Geron Corporation GERN provided an update from two of the ongoing studies on its lead compound imetelstat The stock lost 19 6 on the news touching a new 52 week low of 2 06 on Sep 12 before eventually closing a little higher at 2 30 The company announced that its partner
CORT,CORT:US,BBG000BKJG33,Glaxo/J&J File for Rheumatoid Arthritis Drug Sirukumab in EU,2016-09-13 15:48:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bEZLxcrE8Ek/glaxojj-file-for-rheumatoid-arthritis-drug-sirukumab-in-eu-cm678757,GlaxoSmithKline plc GSK and Johnson amp Johnson s JNJ Janssen Biologics announced the submission of a Marketing Authorisation Application MAA for sirukumab subcutaneous formulation for the treatment of adult patients with moderate to severely active rheumatoid arthritis RA
CORT,CORT:US,BBG000BKJG33,"Auris (EARS) Advances on Sudden Deafness Study, Stock Up",2016-09-12 15:35:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b-YjH8qZdQc/auris-ears-advances-on-sudden-deafness-study-stock-up-cm677949,Auris Medical Holding AG EARS shares were up 15 2 after the company announced that it has attained enrollment midpoint n 125 in the phase III HEALOS study on AM 111 for the treatment of idiopathic sudden sensorineural hearing loss ISSNHL also known as sudden deafness HEALOS
CORT,CORT:US,BBG000BKJG33,4 Growth Stocks at Low Prices to Counter the Market Slump,2016-09-12 13:06:01 +0000,http://finance.yahoo.com/news/4-growth-stocks-low-prices-130601792.html,4 Growth Stocks at Low Prices to Counter the Market Slump
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : September 9, 2016",2016-09-09 17:56:18 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-value-analysis-nasdaqcort-september-9-2016/,"Corcept Therapeutics, Inc. â€“ Value Analysis (NASDAQ:CORT) : September 9, 2016"
CORT,CORT:US,BBG000BKJG33,"Agios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up",2016-09-08 15:21:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oIyyaYJvjew/agios-agio-partner-celgene-to-file-for-enasidenib-stock-up-cm676183,Agios Pharmaceuticals Inc s AGIO shares were up almost 26 after the company revealed in an 8 K filing that its collaboration partner Celgene Corporation CELG will submit a new drug application NDA for enasidenib AG 221 for the treatment of patients with relapsed and or refractory
CORT,CORT:US,BBG000BKJG33,GW Pharmaceuticals (GWPH) Stock Gains on Buyout Rumors,2016-09-08 14:21:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TqDXFBl4D9Q/gw-pharmaceuticals-gwph-stock-gains-on-buyout-rumors-cm676141,GW Pharmaceuticals plc s GWPH shares gained 23 6 after Reuters published a report that many drugmakers have approached the company for a potential acquisition GW Pharma has hired investment bank Morgan Stanley MS for managing the proposals However both GW Pharma and Morgan Stanley
CORT,CORT:US,BBG000BKJG33,5 Stocks Under $10 That Could Make You a Lot of Money,2016-09-08 13:21:00 +0000,https://www.thestreet.com/story/13698364/1/5-stocks-under-10-that-could-make-you-a-lot-of-money.html?puc=yahoo&cm_ven=YAHOO,5 Stocks Under $10 That Could Make You a Lot of Money
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : September 8, 2016",2016-09-08 12:07:49 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-cort-us-september-8-2016/,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : September 8, 2016"
CORT,CORT:US,BBG000BKJG33,Sage Therapeutics: Breakthrough Status for Depression Drug,2016-09-07 17:18:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zvTGkWfNZwM/sage-therapeutics-breakthrough-status-for-depression-drug-cm675738,Sage Therapeutics Inc SAGE announced that the FDA has granted Breakthrough Therapy designation to its experimental drug SAGE 547 which is being developed for the treatment of postpartum depression PPD in women Shares gained more than 12 in yesterday s trading session
CORT,CORT:US,BBG000BKJG33,BioMarin's (BMRN) Brineura Review Period Extended by FDA,2016-09-07 17:18:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yG2wX5Rm2T4/biomarins-bmrn-brineura-review-period-extended-by-fda-cm675724,BioMarin Pharmaceutical Inc BMRN announced that the FDA has extended the review period of its biologics license application BLA for Brineura cerliponase alfa by three months The company is looking to get Brineura approved for the treatment of children with CLN2 disease a form of
CORT,CORT:US,BBG000BKJG33,Karyopharm Reports Positive Multiple Myeloma Study Data,2016-09-07 17:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sPrgZuaFjPA/karyopharm-reports-positive-multiple-myeloma-study-data-cm675721,Karyopharm Therapeutics Inc s KPTI reported encouraging top line results from a phase IIb study on its oncology candidate selinexor The phase IIb STORM study evaluated oral selinexor in combination with low dose dexamethasonein in heavily pretreated multiple myeloma MM patients
CORT,CORT:US,BBG000BKJG33,Bristol-Myers' Orencia Gains EU Approval for Expanded Use,2016-09-07 17:17:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JDaiNWLTAxE/bristol-myers-orencia-gains-eu-approval-for-expanded-use-cm675717,Bristol Myers Squibb Company BMY announced that the European Commission has approved Orencia intravenous IV infusion and subcutaneous SC injection in combination with methotrexate MTX for the treatment of highly active and progressive disease in adult patients with rheumatoid
CORT,CORT:US,BBG000BKJG33,Bristol-Myers' Orencia Gains EU Approval for Expanded Use,2016-09-07 14:59:02 +0000,http://finance.yahoo.com/news/bristol-myers-orencia-gains-eu-145902474.html,Bristol-Myers' Orencia Gains EU Approval for Expanded Use
CORT,CORT:US,BBG000BKJG33,BioMarin's (BMRN) Brineura Review Period Extended by FDA,2016-09-07 14:58:02 +0000,http://finance.yahoo.com/news/biomarins-bmrn-brineura-review-period-145802573.html,BioMarin's (BMRN) Brineura Review Period Extended by FDA
CORT,CORT:US,BBG000BKJG33,Karyopharm Reports Positive Multiple Myeloma Study Data,2016-09-07 14:58:02 +0000,http://finance.yahoo.com/news/karyopharm-reports-positive-multiple-myeloma-145802009.html,Karyopharm Reports Positive Multiple Myeloma Study Data
CORT,CORT:US,BBG000BKJG33,"Zacks.com featured highlights: Corcept Therapeutics, Parsley Energy, TRI Pointe Group, NuVasive and Facebook",2016-09-07 13:22:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GLb9yG-ErWg/zackscom-featured-highlights-corcept-therapeutics-parsley-energy-tri-pointe-group-nuvasive-and-facebook-cm674941,For Immediate Release Chicago IL September 06 2016 Stocks in this week s article include Corcept Therapeutics Incorporated CORT Parsley Energy Inc PE TRI Pointe Group Inc TPH NuVasive Inc NUVA and Facebook Inc FB Screen of the Week of
CORT,CORT:US,BBG000BKJG33,Novartis (NVS) Reports Positive Data on Ultibro Breezhaler,2016-09-06 16:20:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8k__pqJovU/novartis-nvs-reports-positive-data-on-ultibro-breezhaler-cm675059,Novartis Pharma AG NVS announced positive results from a head to head study FLAME on Ultibro Breezhaler at the 2016 European Respiratory Society ERS International Congress The randomized double blinded double dummy parallel group non inferiority active controlled 52 week
CORT,CORT:US,BBG000BKJG33,Catalyst Firdapse Gets Orphan Status for Myasthenia Gravis,2016-09-06 15:21:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vn4KzQG_PDU/catalyst-firdapse-gets-orphan-status-for-myasthenia-gravis-cm674960,Catalyst Pharmaceuticals Inc CPRX announced that the FDA has granted orphan drug designation to Firdapse amifampridine phosphate for the treatment of myasthenia gravis Orphan drug designation is given to drugs being developed for rare diseases disorders that affect less than 200 000
CORT,CORT:US,BBG000BKJG33,"Zacks.com featured highlights: Corcept Therapeutics, Parsley Energy, TRI Pointe Group, NuVasive and Facebook",2016-09-06 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-corcept-133001371.html,"Zacks.com featured highlights: Corcept Therapeutics, Parsley Energy, TRI Pointe Group, NuVasive and Facebook"
CORT,CORT:US,BBG000BKJG33,Array (ARRY) Oncology Drug Accepted for Review in the U.S.,2016-09-02 15:22:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sQUdwgmSqHM/array-arry-oncology-drug-accepted-for-review-in-the-us-cm674007,Array BioPharma ARRY announced that the FDA has accepted a New Drug Application NDA for its pipeline candidate binimetinib The NDA was submitted in Jun 2016 based on positive results from the phase III trial NEMO which compared binimetinib with dacarbazine in unresectable or
CORT,CORT:US,BBG000BKJG33,Bet on These 5 Profitable Stocks for Big Returns,2016-09-02 13:19:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rEiKy-O560g/bet-on-these-5-profitable-stocks-for-big-returns-cm673911,A company with strong profit generating capabilities usually has the proficiency to meet business expenses and create steady returns for investors However if such profitable companies have weak fundamentals they might fail to provide attractive returns Multiple studies show that a company
CORT,CORT:US,BBG000BKJG33,Bet on These 5 Profitable Stocks for Big Returns,2016-09-02 11:26:11 +0000,http://finance.yahoo.com/news/bet-5-profitable-stocks-big-112611344.html,Bet on These 5 Profitable Stocks for Big Returns
CORT,CORT:US,BBG000BKJG33,Roche Immuno-oncology Drug Tecentriq Positive in Phase III,2016-09-01 15:31:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V7l2aZUbYOE/roche-immuno-oncology-drug-tecentriq-positive-in-phase-iii-cm673448,Roche Holding AG RHHBY announced positive results from a phase III study OAK on its immuno oncology drug Tecentriq Data from the study showed that treatment with Tecentriq led to a statistically significant and clinically meaningful improvement in overall survival OS compared to
CORT,CORT:US,BBG000BKJG33,Roche Gets FDA Nod for Emergency Use of Zika Virus Test,2016-08-29 14:14:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gmsXRH8YytU/roche-gets-fda-nod-for-emergency-use-of-zika-virus-test-cm671621,"Roche HoldingsRHHBY announced that the FDA has issued an Emergency Use Authorization (EUA) for its LightMix Zika rRT PCR Test.  Note that the test has, however, not been cleared or approved by the FDA yet. The"
CORT,CORT:US,BBG000BKJG33,Roche Gets FDA Nod for Emergency Use of Zika Virus Test,2016-08-29 12:41:12 +0000,http://finance.yahoo.com/news/roche-gets-fda-nod-emergency-124112948.html,Roche Gets FDA Nod for Emergency Use of Zika Virus Test
CORT,CORT:US,BBG000BKJG33,Novartis (NVS) Reports Positive Phase III Results on MS Drug,2016-08-26 16:31:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ubgubmalurg/novartis-nvs-reports-positive-phase-iii-results-on-ms-drug-cm670807,"Novartis AGNVS announced positive results from the phase III EXPAND study on its pipeline candidate, BAF312 (siponimod).  The randomized, double blinded, placebo controlled study was evaluating the efficacy and safety of once daily oral BAF312 in"
CORT,CORT:US,BBG000BKJG33,Mallinckrodt to Divest Nuclear Imaging Business for $690M,2016-08-25 13:48:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ptM533U_DIQ/mallinckrodt-to-divest-nuclear-imaging-business-for-690m-cm670064,"Mallinckrodt plcMNK announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.  Of the total value of the deal, approximately $574 million comprises up front"
CORT,CORT:US,BBG000BKJG33,Cempra's Application for Pneumonia Drug Validated in EU,2016-08-24 22:45:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B2tySEc7D2s/cempras-application-for-pneumonia-drug-validated-in-eu-cm669809,"Cempra, Inc . CEMP announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community acquired bacterial"
CORT,CORT:US,BBG000BKJG33,Cempra's Application for Pneumonia Drug Validated in EU,2016-08-24 21:02:09 +0000,http://finance.yahoo.com/news/cempras-application-pneumonia-drug-validated-210209666.html,Cempra's Application for Pneumonia Drug Validated in EU
CORT,CORT:US,BBG000BKJG33,Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics,2016-08-24 17:48:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y2PmVdnGABc/novartis-licenses-anti-pcsk9-antibody-to-cyon-therapeutics-cm669456,"Novartis AGNVS entered into a license agreement with privately held Cyon Therapeutics Inc. for its anti PCSK9 antibody, LGT 209, as per a press release issued by the latter.  Although financial details of the agreement were"
CORT,CORT:US,BBG000BKJG33,J&J (JNJ) Seeks EU Approval for Darzalex's Expanded Use,2016-08-24 15:49:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ojxT_KnEwbY/jj-jnj-seeks-eu-approval-for-darzalexs-expanded-use-cm669551,"Johnson & Johnson 's JNJ Janssen Cilag International NV announced that it has filed a type II variation application with the European Medicines Agency seeking label expansion for its immunotherapy, Darzalex, in combination with Revlimid (an immmunomodulatory"
CORT,CORT:US,BBG000BKJG33,Roche Launches Accu-Chek Blood Glucose Monitoring System,2016-08-23 15:49:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1XxBCjW72Zo/roche-launches-accu-chek-blood-glucose-monitoring-system-cm668985,"Roche HoldingsRHHBY announced the launch of a next generation blood glucose (BG) monitoring system, Accu Chek Guide.  The new monitoring system will enable BG monitoring much simpler thanks to its features like the spill resistant SmartPack"
CORT,CORT:US,BBG000BKJG33,Gilead (GILD) Truvada Gets EU Approval for Label Expansion,2016-08-23 15:49:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-X4W6Lyjz9k/gilead-gild-truvada-gets-eu-approval-for-label-expansion-cm668962,"Gilead Sciences Inc.GILD received encouraging news when the European Commission approved its marketing authorization for once daily Truvada (Emtriva 200 mg tenofovir disoproxil 245 mg), making it the first antiretroviral treatment to be approved in Europe for"
CORT,CORT:US,BBG000BKJG33,Gilead (GILD) Truvada Gets EU Approval for Label Expansion,2016-08-23 14:02:02 +0000,http://finance.yahoo.com/news/gilead-gild-truvada-gets-eu-140202999.html,Gilead (GILD) Truvada Gets EU Approval for Label Expansion
CORT,CORT:US,BBG000BKJG33,Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults,2016-08-22 15:48:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OciS-AU0gVU/supernus-trokendi-xr-gets-fda-nod-for-migraine-in-adults-cm668425,"Supernus Pharmaceuticals, Inc.SUPN announced that the FDA has granted a tentative approval to the company's supplemental New Drug Application (sNDA) for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.  We"
CORT,CORT:US,BBG000BKJG33,"ETFâ€™s with exposure to Corcept Therapeutics, Inc. : August 22, 2016",2016-08-22 15:16:56 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-corcept-therapeutics-inc-august-22-2016/,"ETFâ€™s with exposure to Corcept Therapeutics, Inc. : August 22, 2016"
CORT,CORT:US,BBG000BKJG33,What Falling Estimates & Price Mean for Merus Labs International (MSLI),2016-08-22 14:48:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/28-9aQOT8Qc/what-falling-estimates-price-mean-for-merus-labs-international-msli-cm668370,"Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to"
CORT,CORT:US,BBG000BKJG33,Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults,2016-08-22 13:52:01 +0000,http://finance.yahoo.com/news/supernus-trokendi-xr-gets-fda-135201529.html,Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults
CORT,CORT:US,BBG000BKJG33,What Falling Estimates & Price Mean for Merus Labs International (MSLI),2016-08-22 12:43:12 +0000,http://finance.yahoo.com/news/falling-estimates-price-mean-merus-124312449.html,What Falling Estimates & Price Mean for Merus Labs International (MSLI)
CORT,CORT:US,BBG000BKJG33,"Valeant Stock Down on Lawsuit by T. Rowe, Alters Credit Loan",2016-08-22 10:47:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Poq_E1GFhSE/valeant-stock-down-on-lawsuit-by-t-rowe-alters-credit-loan-cm667833,"Valeant Pharmaceuticals International, Inc . VRX announced that it has received the requisite lender approval for an amendment to its credit facility which is scheduled to close next week. The amendment will result in a reduction in"
CORT,CORT:US,BBG000BKJG33,Insys Therapeutics Starts Enrollment in Cannabidiol Trial,2016-08-19 23:42:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dJky_rP8-Y0/insys-therapeutics-starts-enrollment-in-cannabidiol-trial-cm668017,"Insys Therapeutics, Inc . INSY announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.  The candidate is being evaluated for the treatment of cocaine dependence."
CORT,CORT:US,BBG000BKJG33,Horizon (HZNP) Rayos Receives USPTO Notice of Allowance,2016-08-19 16:48:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TKDXDRaqjhM/horizon-hznp-rayos-receives-uspto-notice-of-allowance-cm667831,"Horizon Pharma plcHZNP announced that the U.S. Patent and Trademark Office (USPTO) has issued an additional notice of allowance for U.S. patent application number 14 563,000 with claims covering Rayos (prednisone) delayed release tablets.  The notice"
CORT,CORT:US,BBG000BKJG33,Horizon (HZNP) Rayos Receives USPTO Notice of Allowance,2016-08-19 14:22:02 +0000,http://finance.yahoo.com/news/horizon-hznp-rayos-receives-uspto-142202139.html,Horizon (HZNP) Rayos Receives USPTO Notice of Allowance
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : August 19, 2016",2016-08-19 12:20:35 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-cort-us-august-19-2016/,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : August 19, 2016"
CORT,CORT:US,BBG000BKJG33,Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study,2016-08-17 22:47:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cth52lAZsdA/glaxopfizer-viiv-healthcare-starts-hiv-drug-combo-study-cm666638,"GlaxoSmithKlineGSK announced that its HIV focused company, ViiV Healthcare has initiated a phase III program to support regulatory filings for a two drug regimen of Tivicay and Epivir for the treatment for HIV 1 infection in adults who have"
CORT,CORT:US,BBG000BKJG33,OncoGenex Down on Poor Phase III Data on Lead Cancer Drug,2016-08-17 22:07:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RLtYBd48Hio/oncogenex-down-on-poor-phase-iii-data-on-lead-cancer-drug-cm666520,"Shares of OncoGenex Pharmaceuticals, Inc . OGXI were down 41% after the company announced disappointing data from its late stage trial, AFFINITY, on custirsen in men with metastatic castrate resistant prostate cancer (CRPC) whose disease has progressed after treatment"
CORT,CORT:US,BBG000BKJG33,Endo (ENDP) Withdraws Label Expansion Filing for Opana ER,2016-08-16 22:32:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/elWdKM7ir8s/endo-endp-withdraws-label-expansion-filing-for-opana-er-cm666243,"Late last week, Endo International plcENDP announced that the company has decided to withdraw its supplemental new drug application (sNDA) related to specific abuse deterrent labeling for Opana ER without prejudice to re filing, following discussions with the FDA"
CORT,CORT:US,BBG000BKJG33,Endo (ENDP) Withdraws Label Expansion Filing for Opana ER,2016-08-16 20:48:08 +0000,http://finance.yahoo.com/news/endo-endp-withdraws-label-expansion-204808641.html,Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
CORT,CORT:US,BBG000BKJG33,Aurinia (AUPH) Stock Falls on Poor Phase II Lupus Study Data,2016-08-16 17:38:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yPVs30xAiAs/aurinia-auph-stock-falls-on-poor-phase-ii-lupus-study-data-cm666060,"Shares of Aurinia Pharmaceuticals Inc.AUPH crashed 55% after the company reported results from a phase IIb study, AURA LV, on its pipeline candidate, voclosporin, in patients with active lupus nephritis (LN). The randomized, controlled, double blind study compared the"
CORT,CORT:US,BBG000BKJG33,Bristol-Myers to Reacquire Rights to Oncology Drug in Asia,2016-08-15 15:40:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vq7zcySJze0/bristol-myers-to-reacquire-rights-to-oncology-drug-in-asia-cm665322,"Bristol Myers Squibb CompanyBMY will reacquire the rights to ASLAN002 (BMS777607) from privately held biotech company, Aslan Pharmaceuticals, as announced by the latter. Reacquired rights cover the territories of China, Australia, Korea, Taiwan and other Asian countries. Aslan, an"
CORT,CORT:US,BBG000BKJG33,Bristol-Myers to Reacquire Rights to Oncology Drug in Asia,2016-08-15 13:26:01 +0000,http://finance.yahoo.com/news/bristol-myers-reacquire-rights-oncology-132601994.html,Bristol-Myers to Reacquire Rights to Oncology Drug in Asia
CORT,CORT:US,BBG000BKJG33,Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value,2016-08-12 18:49:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rTDr8tVuNEg/mallinckrodt-mnk-to-buy-stratatech-for-undisclosed-value-cm664814,"Mallinckrodt plcMNK announced that it will acquire privately held regenerative medicine company, Stratatech Corporation. However, financial terms of the transaction were not disclosed. The transaction will close in the second half of the year. Assets Acquired through the Deal"
CORT,CORT:US,BBG000BKJG33,Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value,2016-08-12 16:24:04 +0000,http://finance.yahoo.com/news/mallinckrodt-mnk-buy-stratatech-undisclosed-162404386.html,Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value
CORT,CORT:US,BBG000BKJG33,"ETFâ€™s with exposure to Corcept Therapeutics, Inc. : August 11, 2016",2016-08-11 16:39:59 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-corcept-therapeutics-inc-august-11-2016/,"ETFâ€™s with exposure to Corcept Therapeutics, Inc. : August 11, 2016"
CORT,CORT:US,BBG000BKJG33,Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss,2016-08-11 15:55:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_hcpT-V2EX4/adverum-advm-reports-narrower-than-expected-q2-loss-cm664092,"Adverum Biotechnologies, Inc . ADVM reported a loss of 36 cents in the second quarter of 2016, narrower than both the Zacks Consensus Estimate and the year ago loss of 38 cents. With no approved product in its portfolio"
CORT,CORT:US,BBG000BKJG33,Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss,2016-08-11 13:31:01 +0000,http://finance.yahoo.com/news/adverum-advm-reports-narrower-expected-133101605.html,Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
CORT,CORT:US,BBG000BKJG33,"Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib",2016-08-11 11:53:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DoCYkwVdAKQ/puma-pbyi-posts-narrower-loss-in-q2-focus-on-neratinib-cm663514,"Puma Biotechnology, Inc.PBYI reported a second quarter 2016 loss of $2.05 per share, much narrower than the Zacks Consensus Estimate of $2.20 but wider than the year ago loss of $2.01. With no approved product in Puma Biotech's portfolio"
CORT,CORT:US,BBG000BKJG33,GW Pharma (GWPH) Incurs Narrower-than-Expected Q3 Loss,2016-08-10 20:51:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E4lyYN9XTGo/gw-pharma-gwph-incurs-narrower-than-expected-q3-loss-cm663653,"GW Pharmaceuticals, Inc.GWPH reported a third quarter fiscal 2016 (for the three months ended Jun 30, 2016) loss of 73 cents per share, much narrower than the Zacks Consensus Estimate of a loss of $1.73. The reported loss was"
CORT,CORT:US,BBG000BKJG33,GW Pharma (GWPH) Incurs Narrower-than-Expected Q3 Loss,2016-08-10 18:57:06 +0000,http://finance.yahoo.com/news/gw-pharma-gwph-incurs-narrower-185706392.html,GW Pharma (GWPH) Incurs Narrower-than-Expected Q3 Loss
CORT,CORT:US,BBG000BKJG33,"Mylan Beats on Q2 Earnings, Revenues Miss, Keeps '16 View",2016-08-10 16:53:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mfbsozgqwR0/mylan-beats-on-q2-earnings-revenues-miss-keeps-16-view-cm663519,Mylan N.V. 's MYL second quarter 2016 earnings of $1.16 per share beat the Zacks Consensus Estimate by a penny. Reported earnings soared 28% from the year ago quarter. Mylan Inc. (MYL) Street EPS & Surprise Percent Last 5
CORT,CORT:US,BBG000BKJG33,Catalyst (CPRX) Reports Narrower-than-Expected Q2 Loss,2016-08-10 16:53:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M5FeIble5Rs/catalyst-cprx-reports-narrower-than-expected-q2-loss-cm663517,"Catalyst Pharmaceuticals, Inc.CPRX reported a loss of 6 cents per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 8 cents and in line with the year ago loss of 6"
CORT,CORT:US,BBG000BKJG33,"Perrigo (PRGO) Misses Q2 Earnings Estimates, Cuts '16 View",2016-08-10 16:49:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zG_PJNgXnp8/perrigo-prgo-misses-q2-earnings-estimates-cuts-16-view-cm663474,Perrigo Company plc 's PRGO second quarter 2016 earnings of $1.93 per share fell short of the Zacks Consensus Estimate of $2.00. Reported earnings also declined 11% from the year ago figure. Perrigo Company (PRGO) Street EPS & Surprise
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016",2016-08-10 15:58:45 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-cort-us-earnings-analysis-q2-2016-by-the-numbers-august-10-2016/,"Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016"
CORT,CORT:US,BBG000BKJG33,"Jazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook",2016-08-10 13:28:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ebQzgMeQ8AU/jazz-jazz-q2-earnings-up-yy-lowers-earnings-outlook-cm663077,"Jazz Pharmaceuticals plcJAZZ reported second quarter 2016 earnings of $1.80 per share, up 28.6% from the year ago period. The Zacks Consensus Estimate was $1.71 per share. Excluding one time items, second quarter 2016 earnings increased 15.4% to $2.63"
CORT,CORT:US,BBG000BKJG33,"Horizon (HZNP) Earnings Up Y/Y, Keeps '16 View, Stock Up",2016-08-09 19:55:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ALAZ6s-XMjw/horizon-hznp-earnings-up-yy-keeps-16-view-stock-up-cm662800,"Horizon Pharma plc 's HZNP second quarter 2016 earnings (under new methodology) of 56 cents per share increased 51.4% from the year ago period. Under the prior methodology, the company reported second quarter earnings of 62 cents per share,"
CORT,CORT:US,BBG000BKJG33,Why Corcept Therapeutics (CORT) Could Be a Potential Winner,2016-08-09 15:38:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gnG389fTBNc/why-corcept-therapeutics-cort-could-be-a-potential-winner-cm662549,"It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing"
CORT,CORT:US,BBG000BKJG33,"Endo (ENDP) Tops Q2 Earnings Estimates, Keeps 2016 View",2016-08-09 15:37:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kt1uN1Beau0/endo-endp-tops-q2-earnings-estimates-keeps-2016-view-cm662522,"Endo International plc 's ENDP second quarter 2016 earnings of 86 cents per share significantly beat the Zacks Consensus Estimate of 75 cents. However, reported earnings decreased 20% from the year ago period. Revenues came in at $920.9 million"
CORT,CORT:US,BBG000BKJG33,"Inovio (INO) Q2 Loss in Line with Estimates, Revenues Top",2016-08-09 15:37:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/66tdMq0-Qts/inovio-ino-q2-loss-in-line-with-estimates-revenues-top-cm662519,"Inovio Pharmaceuticals, Inc.INO reported a loss of 26 cents per share in the second quarter of 2016, in line with the Zacks Consensus Estimate but wider than the year ago loss of 9 cents. Inovio Pharmaceuticals Inc. (INO) Street"
CORT,CORT:US,BBG000BKJG33,Why Corcept Therapeutics (CORT) Could Be a Potential Winner,2016-08-09 13:06:01 +0000,http://finance.yahoo.com/news/why-corcept-therapeutics-cort-could-130601791.html,Why Corcept Therapeutics (CORT) Could Be a Potential Winner
CORT,CORT:US,BBG000BKJG33,"Zacks.com featured highlights: Logitech International SA, A10 Networks, TriNet Group, Corcept Therapeutics and Antero Resources",2016-08-09 11:22:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-xyH07Ecr0E/zackscom-featured-highlights-logitech-international-sa-a10-networks-trinet-group-corcept-therapeutics-and-antero-resources-cm661776,"For Immediate Release Chicago, IL August 08, 2016 Stocks in this week's article include Logitech International SA ( LOGI ), A10 Networks, Inc. ( ATEN ), TriNet Group, Inc. ( TNET ), Corcept Therapeutics Incorporated ( CORT ) and"
CORT,CORT:US,BBG000BKJG33,Endocyte (ECYT) Q2 Loss Wider than Expected (Revised),2016-08-09 11:16:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9edhoNESOy4/endocyte-ecyt-q2-loss-wider-than-expected-revised-cm662242,"Endocyte, Inc.ECYT reported a second quarter 2016 loss of 33 cents per share, wider than both the Zacks Consensus Estimate of a loss of 26 cents and the year ago loss of 25 cents. On the other hand, the"
CORT,CORT:US,BBG000BKJG33,"Zacks.com featured highlights: Logitech International SA, A10 Networks, TriNet Group, Corcept Therapeutics and Antero Resources",2016-08-08 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-logitech-133001398.html,"Zacks.com featured highlights: Logitech International SA, A10 Networks, TriNet Group, Corcept Therapeutics and Antero Resources"
CORT,CORT:US,BBG000BKJG33,Egalet (EGLT) Catches Eye: Stock Adds 6.8% in Session,2016-08-08 12:25:12 +0000,http://finance.yahoo.com/news/egalet-eglt-catches-eye-stock-122512150.html,Egalet (EGLT) Catches Eye: Stock Adds 6.8% in Session
CORT,CORT:US,BBG000BKJG33,5 Liquid Stocks for a Steady Flow of High Returns,2016-08-05 14:23:02 +0000,http://finance.yahoo.com/news/5-liquid-stocks-steady-flow-142302506.html,5 Liquid Stocks for a Steady Flow of High Returns
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : August 3, 2016",2016-08-03 14:31:21 +0000,http://www.capitalcube.com/blog/index.php/corcept-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-cort-us-august-3-2016/,"Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : August 3, 2016"
CORT,CORT:US,BBG000BKJG33,"CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report",2016-08-03 10:07:46 +0000,http://biz.yahoo.com/e/160803/cort10-q.html,"CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report"
CORT,CORT:US,BBG000BKJG33,Edited Transcript of CORT earnings conference call or presentation 2-Aug-16 9:00pm GMT,2016-08-03 06:52:32 +0000,http://finance.yahoo.com/news/edited-transcript-cort-earnings-conference-065232166.html,Edited Transcript of CORT earnings conference call or presentation 2-Aug-16 9:00pm GMT
CORT,CORT:US,BBG000BKJG33,Corcept beats 2Q profit forecasts,2016-08-02 21:08:31 +0000,http://sg.finance.yahoo.com/news/corcept-beats-2q-profit-forecasts-210831841.html,Corcept beats 2Q profit forecasts
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update,2016-08-02 20:42:08 +0000,http://www.publicnow.com/view/F007B6529AE24D0CF4CFDA9C13528E8AD5DEB206,[at noodls] - Corcept Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update The text version of this document is not available at the moment. The original content was posted at original ...
CORT,CORT:US,BBG000BKJG33,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-08-02 20:25:35 +0000,http://biz.yahoo.com/e/160802/cort8-k.html,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
CORT,CORT:US,BBG000BKJG33,Q2 2016 Corcept Therapeutics Inc Earnings Release - After Market Close,2016-08-02 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20160802.html?t=cort,Q2 2016 Corcept Therapeutics Inc Earnings Release - After Market Close
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics to Announce Second Quarter 2016 Financial Results and Corporate Update and Host Conference Call,2016-07-26 20:48:04 +0000,http://www.publicnow.com/view/2A32024CFF522B86BA809FB52DA67C1F11F9D9F2,"[at noodls] - Download this Press Release Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 2, 2016. ..."
CORT,CORT:US,BBG000BKJG33,Everybody's Doing It: 5 Stocks Under $10 That I Like,2016-07-14 16:22:00 +0000,http://realmoney.thestreet.com/articles/07/14/2016/everybodys-doing-it-5-stocks-under-10-i?puc=yahoo&cm_ven=YAHOO,Everybody's Doing It: 5 Stocks Under $10 That I Like
CORT,CORT:US,BBG000BKJG33,"Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust",2016-06-29 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-arcos-133001065.html,"Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust"
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Appoints RenÃ©e D. GalÃ¡ to Board of Directors,2016-06-28 21:11:03 +0000,http://www.publicnow.com/view/0EF88A30EAD0A776DC58360A8C6BBB8AF623224F,"[at noodls] - Download this Press Release Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe ..."
CORT,CORT:US,BBG000BKJG33,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi",2016-06-28 20:39:50 +0000,http://biz.yahoo.com/e/160628/cort8-k.html,"CORCEPT THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi"
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Appoints Renee D. Gala to Board of Directors,2016-06-28 20:05:00 +0000,http://finance.yahoo.com/news/corcept-therapeutics-appoints-renee-d-200500229.html,"[Marketwired] - Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating ..."
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program,2016-06-02 21:15:07 +0000,http://www.publicnow.com/view/4B4BA319300EC796BE1F0508971E62E8705B95AA,[at noodls] - Download this Press Release Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai's Halaven) to treat triple-negative breast cancer (TNBC) indicate combination ...
CORT,CORT:US,BBG000BKJG33,"AKAO Abuzz, AAAP Gets FDA Blessing, CORT Under Close Watch, Big Day For MBRX",2016-06-02 20:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sXElo_ncTGY/akao-abuzz-aaap-gets-fda-blessing-cort-under-close-watch-big-day-for-mbrx-20160602-01260,"AKAO Abuzz, AAAP Gets FDA Blessing, CORT Under Close Watch, Big Day For MBRX"
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update,2016-05-03 21:10:08 +0000,http://www.publicnow.com/view/137B1B95F85F88966302436FC53D174073CEA53B,"[at noodls] - Download this Press Release First quarter revenue of $16.1 million, a 59 percent increase from the first quarter of 2015 Excluding non-cash expenses, first quarter non-GAAP net income of $0.02 ..."
CORT,CORT:US,BBG000BKJG33,Corcept beats 1Q profit forecasts,2016-05-03 20:35:41 +0000,http://sg.finance.yahoo.com/news/corcept-beats-1q-profit-forecasts-203541051.html,Corcept beats 1Q profit forecasts
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call,2016-04-29 14:50:16 +0000,http://www.publicnow.com/view/DC32EDF52BE6127DAE5004DCF653EEC4C5826831,"[at noodls] - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 3, 2016. The Company will also host a conference call ..."
CORT,CORT:US,BBG000BKJG33,Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushingâ€™s Syndrome and Solid-Tumor Cancers,2016-04-28 21:31:04 +0000,http://www.publicnow.com/view/E4C660B35AB97A982841B00D6E5E8B5EEE49B713,"[at noodls] - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders ..."
CORT,CORT:US,BBG000BKJG33,Corcept beats 4Q profit forecasts,2016-03-01 22:31:46 +0000,http://sg.finance.yahoo.com/news/corcept-beats-4q-profit-forecasts-223146391.html,Corcept beats 4Q profit forecasts
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics Announces Preliminary Fourth Quarter and Full Year 2015 Summary Financial Results, Provides 2016 Revenue Guidance and Corporate Update",2016-01-28 22:17:10 +0000,http://www.publicnow.com/view/743EF79F32A6A6691DF057CB197193EE23BB8445,"[at noodls] - Full year 2015 revenue of $50.3 million, an 89 percent increase from 2014 Fourth quarter 2015 revenue of $15.0 million, a 66 percent increase from the fourth quarter of 2014 2016 revenue guidance is $76-81 ..."
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance and Corporate Update, and Host Conference Call",2016-01-22 16:13:10 +0000,http://www.noodls.com/view/4E148CD0066032C1E007A3856DD875180708A7F3,[at noodls] - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2015 financial results and provide 2016 revenue guidance and a corporate update ...
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in Combination With Eribulin for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer,2015-12-14 15:14:21 +0000,http://www.noodls.com/view/E7826090AC88E8109236A2EE66C29B9069C99E56,"[at noodls] - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders ..."
CORT,CORT:US,BBG000BKJG33,Corcept reports 3Q loss,2015-11-05 23:45:47 +0000,http://sg.finance.yahoo.com/news/corcept-reports-3q-loss-234547241.html,Corcept reports 3Q loss
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics Announces Third Quarter 2015 Results and Provides Corporate Update,2015-11-05 22:53:03 +0000,http://www.noodls.com/view/1487DE1F2CBEFBAF763F78E2BC9E400F4EEC93EC,"[at noodls] - GAAP net loss in the third quarter narrows to $0.6 million, from $6.0 million in the third quarter of 2014 Non-GAAP net income in the third quarter increases to $1.6 million, compared to a non-GAAP net ..."
CORT,CORT:US,BBG000BKJG33,Corcept Therapeutics To Announce Third Quarter Financial Results and Corporate Update and Host Conference Call,2015-10-29 20:58:05 +0000,http://www.noodls.com/view/EAE041A64396B4E47CA1265D0C9E72ADE6F44E92,"[at noodls] - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 5, 2015. The Company will also host a conference ..."
CORT,CORT:US,BBG000BKJG33,Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists,2015-10-13 21:18:13 +0000,http://www.noodls.com/view/8E93BD0E3F1C5750750189859E601CAAF6B8767C,"[at noodls] - Design and outcome of trial to be discussed in webinar broadcast October 14, 2015 Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization ..."
CORT,CORT:US,BBG000BKJG33,"Corcept Therapeutics Appoints Robert S. Fishman, M.D., as Chief Medical Officer",2015-09-28 18:37:04 +0000,http://www.noodls.com/view/54950F5767074FEBC9A3BFAAECC6B5438C924AD3,"[at noodls] - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric ..."
CORT,CORT:US,BBG000BKJG33,STRONGBRIDGE BIOPHARMA PLC ANNOUNCES LAUNCH OF ITS PROPOSED INITIAL U.S. PUBLIC OFFERING,2015-09-21 21:05:13 +0000,http://www.noodls.com/view/1919FDA1C86A2D01E1E3E2808A3544F1A3DD8FF2,[at noodls] - STRONGBRIDGE BIOPHARMA PLC ANNOUNCES LAUNCH OF ITS PROPOSED INITIAL U.S. PUBLIC OFFERING
CORT,CORT:US,BBG000BKJG33,"Strongbridge Biopharma plc Announces Appointment of Garheng Kong, M.D., Ph.D., MBA, to its Board of Directors",2015-09-15 06:37:05 +0000,http://www.noodls.com/view/58E5216772E5B498A531A8BD8DF38D579C88CE68,"[at noodls] - Strongbridge Biopharma plc Announces Appointment of Garheng Kong, M.D., Ph.D., MBA, to its Board of Directors"
CORT,CORT:US,BBG000BKJG33,"Interim Financial Results For The Six Months Ended June 30, 2015",2015-09-07 04:46:21 +0000,http://www.noodls.com/view/7A203397D007C98C1DB6F7AED75B68003D60EDDB,"[at noodls] - Interim Financial Results For The Six Months Ended June 30, 2015"
CORT,CORT:US,BBG000BKJG33,Strongbridge Biopharma plc Announces Appointment of Matthew Pauls to its Board of Directors,2015-09-04 18:06:09 +0000,http://www.noodls.com/view/A777F2503EEBE3D52C10723842295EF9AF115D45,[at noodls] - Strongbridge Biopharma plc Announces Appointment of Matthew Pauls to its Board of Directors
CORT,CORT:US,BBG000BKJG33,Cortendo plc Changes Name to Strongbridge Biopharma plc,2015-09-04 16:46:13 +0000,http://www.noodls.com/view/93F316F9AA9EF49706B7F3D7FEB15C43317606EC,[at noodls] - Cortendo plc Changes Name to Strongbridge Biopharma plc
CORT,CORT:US,BBG000BKJG33,Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering,2015-08-31 06:42:03 +0000,http://www.noodls.com/view/E3D5A43230F52CD2E3F36BD0149B00DE698162DF,[at noodls] - Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering
CORT,CORT:US,BBG000BKJG33,Corcept reports 1Q loss,2015-05-07 21:45:47 +0000,http://sg.finance.yahoo.com/news/corcept-reports-1q-loss-214547839.html,Corcept reports 1Q loss
CORT,CORT:US,BBG000BKJG33,Corcept reports 4Q loss,2015-03-04 21:54:36 +0000,http://sg.finance.yahoo.com/news/corcept-reports-4q-loss-215436285.html,Corcept reports 4Q loss
CORT,CORT:US,BBG000BKJG33,Corcept posts 3Q loss,2014-11-04 23:15:55 +0000,http://sg.finance.yahoo.com/news/corcept-posts-3q-loss-231555862--finance.html,Corcept posts 3Q loss
